Renal association clinical practice guideline in post-operative care in the kidney transplant recipient by Baker, Richard J. et al.
CORRESPONDENCE Open Access
Renal association clinical practice guideline
in post-operative care in the kidney
transplant recipient
Richard J. Baker1*†, Patrick B. Mark2†, Rajan K. Patel2, Kate K. Stevens2 and Nicholas Palmer3
Abstract
These guidelines cover the care of patients from the period following kidney transplantation until the transplant is
no longer working or the patient dies. During the early phase prevention of acute rejection and infection are the
priority. After around 3–6 months, the priorities change to preservation of transplant function and avoiding the
long-term complications of immunosuppressive medication (the medication used to suppress the immune system
to prevent rejection). The topics discussed include organization of outpatient follow up, immunosuppressive
medication, treatment of acute and chronic rejection, and prevention of complications. The potential complications
discussed include heart disease, infection, cancer, bone disease and blood disorders. There is also a section on
contraception and reproductive issues.
Immediately after the introduction there is a statement of all the recommendations. These recommendations are
written in a language that we think should be understandable by many patients, relatives, carers and other
interested people. Consequently we have not reworded or restated them in this lay summary. They are graded 1 or
2 depending on the strength of the recommendation by the authors, and AD depending on the quality of the
evidence that the recommendation is based on.
Introduction
This document is intended for those engaged in the care
of kidney transplant recipients (KTR) who are non-
experts. With increasing efforts to deliver health care lo-
cally, many renal transplant recipients are followed up in
centres remote from the main surgical transplant unit.
At the same time, transplantation medicine has evolved
into an increasingly complex and specialised field of
nephrology. The following guidelines reflect this alter-
ation in clinical practice and are intended for those
healthcare professionals who look after renal transplant
patients. They are also intended to be useful to both
medical and surgical trainees, general practitioners,
nurse specialists and other associated healthcare profes-
sionals involved in the care of renal transplant patients.
These guidelines cover the period after renal trans-
plantation, specifically from initial hospital discharge
until graft failure or patient death. The management of
KTR can be divided into two phases:
a. an early post-operative phase when prevention of
acute rejection, optimization of graft function and
prevention of opportunistic infection are paramount
b. a later phase when the aims are to preserve good
graft function, ensure adherence to medication, and
prevent the long-term consequences of immunosup-
pression – malignancy, infection and premature car-
diovascular disease.
The transition between these two phases occurs
around 3–6 months after transplantation at the time
when the progressive, protocolised reduction in im-
munosuppression following transplantation reaches
long-term maintenance levels. Management of the early
and late phase complications of transplantation re-
quires monitoring at reducing frequency, awareness of
complications, access to investigation, and strategies
for prevention and treatment of complications (ranging
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from early acute rejection, to late cardiovascular dis-
ease). There are regional differences in demographics,
risk and organisation of services. The priority is
agreement of local strategies for post-transplant
management.
These guidelines are designed to complement those
previously published relating to pre-transplant care.
It should be noted that other comprehensive guide-
lines have been published and reference will be made to
these [105]. In keeping with other guidelines issued by
the Renal Association, we have used the modified
GRADE system. This grading system classifies expert
recommendations as ‘strong’ (Grade 1) or ‘weak’ (Grade
2) based upon balance between the benefits and risks,
burden and cost. The quality or level of evidence is des-
ignated as high (Grade A), moderate (Grade B), low
(Grade C) or very low (D) depending on factors such as
study design, directness of evidence and consistency of
results. Grades of recommendation and quality of evi-
dence may range from 1A to 2D [129, 210].
These guidelines are based upon systematic literature
searches conducted between November 2014 and
February 2016. The main searches were performed in
November-December 2014 and then rerun in February
2016. We searched Pubmed/MEDLINE, the Cochrane
database of systematic reviews and hand searched refer-
ence lists and articles identified by the writing group
members up till March 2016. We also reviewed all re-
lated guidelines from the National Institute for Clinical
Excellence, NHS Blood and Transplant, the Advisory
Committee on the Safety of Blood, Tissues and Organs
(SaBTO), Kidney Disease Improving Global outcomes
(KDIGO), the European Renal Association Best Practice
Guidelines, Caring for Australians with Renal Impair-
ment (CARI) and American Society of Transplant Sur-
geons. We cross-referenced with the previous iteration
of these guidelines. The Pubmed search terms used were
‘kidney transplant’ AND rejection/rejection/immunosup-
pression/cancer/cardiovascular/diabetes/obesity/smok-
ing/hypertension/pregnancy/gout/infection/vaccination/
fertility/pregnancy.
Summary of clinical practice guidelines for the
post-operative care of the kidney transplant
recipient
Kidney Transplant Recipient (KTR): organisation of
outpatient follow-up (guidelines 1.1–1.4)
Guideline 1.1 – KTR: clinic infrastructure
We suggest that the following infrastructure should be
in place for KTR follow up (2D):
 A consultant-level health care professional should be
available for every transplant clinic
 KTRs should be reviewed in a dedicated outpatient
area
 The results of blood tests (including drug levels if
possible) should be available within 24 h
 A formal mechanism should exist for results review
by health care professionals within 24 h of a clinic
appointment
 There should be access to a multidisciplinary renal
team including pharmacist, dietician, social worker
and psychologist
 Patient care should be planned along principles set
out in the National Service Framework and “Kidney
Health Delivering Excellence”
Guideline 1.2 – KTR: clinic frequency
We suggest that uncomplicated patients may be
reviewed progressively less frequently (2C)
 2–3 times weekly for the first month after
transplantation
 1–2 times weekly for months 2–3
 Every 2–4 weeks for months 4–6
 Every 4–6 weeks for months 6–12
 3–6 monthly thereafter
Guideline 1.3 – KTR: patient access
We suggest that all patients should have access to
support services and results. (2C)
 All patients should have the option of on-line access
to their results via the “Patient View” service
 All patients should have open access to the renal
transplant outpatient service and have an established
point of contact for enquiries
 Patient information should be available in both
written and electronic formats
Guideline 1.4 – KTR: chronic transplant care review
We suggest that a detailed review should be performed
annually post-operatively (2C)
 A process should exist for patient review on an
annual basis in a different format of clinic according
to the “Care plan model”
 This should be a patient-centred clinic, facilitated by
a health care professional
 It should address concerns in medical, social,
psychological and sexual domains
 Access to a renal dietician, social worker, specialist
renal pharmacist and/or psychologist should be
readily available from this clinic
 This process should proceed in parallel with formal
medical review
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Kidney Transplant Recipient: Non-adherence (Guideline 2.1)
Guideline 2.1 – KTR: recognising non-adherence
We suggest that it is important to prevent and detect
non-adherence in kidney transplant recipients. (2C)
 Factors associated with non-adherence should be
identified
 An established interventional pathway should be in
place for those at high risk of or with proven non-
adherence
 Pathways should be in place for paediatric KTRs in
transition and for adolescent KTRs
Kidney Transplant Recipient: immunosuppressive
treatment (Guidelines 3.1–3.12)
Guideline 3.1 – KTR: immunosuppression regimen
We recommend that the patient and/or carer should be
engaged in the decisions around selection of induction
agent and maintenance immunosuppression (1D)
Guideline 3.2 – KTR: induction immunosuppression
We recommend induction therapy should take into
account the following:
 Immunosuppressive drugs should be started before
or at the time of renal transplantation (1B)
 Induction therapy with biological agents should be
administered to all KTRs. In patients at low
immunological risk this will generally involve an
interleukin-2 receptor antagonist (IL2-RA). Recipients
at higher immunological risk may be considered for
T-cell (lymphocyte) depleting antibodies (TDAs) (1B)
 Induction therapy with TDAs may also be useful for
lower immunological risk patients with the intention
of either steroid or calcineurin inhibitor (CNI)
avoidance (1C)
Guideline 3.3 – KTR: induction immunosuppression
We suggest that a CNI should be started at the time of
transplantation and not delayed until the graft is func-
tioning (2C)
Guideline 3.4 – KTR: maintenance immunosuppression
We recommend that maintenance immunosuppression
should normally consist of a calcineurin inhibitor (CNI)
and an anti-proliferative agent, with or without corticoste-
roids in low and medium immunological risk KTRs (1B)
Guideline 3.4 – KTR: maintenance immunosuppression
We suggest that low-medium dose tacrolimus (trough
target 4–8 ng/mL) is recommended as the CNI of choice
in patients also taking steroids who are low and medium
immunological risk and are not at high risk of develop-
ing post transplant diabetes mellitus (PTDM) (2C)
Guideline 3.5 – KTR: maintenance immunosuppression
We suggest that mycophenolic acid -based drugs should
be the first-line anti-proliferative agent in preference to
azathioprine, except in fertile KTRs who are unwilling to
use reliable contraception (2B)
Guideline 3.5 – KTR: maintenance immunosuppression
We suggest that slow release tacrolimus may be used as
an option as second line agents for patients who suffer
intolerable side effects related to peak dose toxicity (2C)
Guideline 3.6 – KTR: maintenance immunosuppression
We suggest that KTRs who are unable to tolerate tacroli-
mus or who suffer serious adverse reactions related to its
use be considered for the use of second line agents such
as ciclosporin, sirolimus, everolimus, or belatacept (1B)
Guideline 3.7 – KTR: maintenance immunosuppression
We suggest that MPA-based drugs should be the first-
line antiproliferative agent, in preference to azathioprine,
except in fertile KTRs who are unwilling to use reliable
contraception (2B)
Guideline 3.8 – KTR: maintenance immunosuppression
We suggest that mycophenolate mofetil (MMF) and
enteric-coated mycophenolate sodium (Myfortic®) provide
equivalent maintenance immunosuppression (2B)
Guideline 3.9 – KTR: maintenance immunosuppression
We suggest that steroid avoidance or steroid withdrawal
can be used during the first week after transplantation in
low immunological risk kidney transplant recipients (2B)
Guideline 3.10 – KTR: maintenance immunosuppression
We suggest aiming for minimum target levels for CNIs in
uncomplicated renal transplantation after 3 months (2C)
Guideline 3.11 – KTR: maintenance immunosuppression
We suggest that CNIs should not be withdrawn (2B)
Guideline 3.12 – KTR: maintenance immunosuppression
We suggest that if steroids are not withdrawn within the
first month, then they should be continued at low dose
(prednisolone 5 mg per day or less) (2C)
Guideline 3.13 – KTR: monitoring of immunosuppression
We suggest that long-term monitoring of immunosup-
pression levels is required as follows:
 Tacrolimus and ciclosporin levels should be
monitored. The initial frequency should be 3 times a
week. Levels should also be checked when any
medication with possible interactions is prescribed,
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the dosage is changed, the formulation is changed,
or when there is unexplained graft dysfunction (2C)
 Tacrolimus should be monitored by the trough (C0)
level, while ciclosporin can be monitored by either
C0 or 2-h post dose (C2) level (2C)
 Tacrolimus and ciclosporin levels should be
available within 24 h of taking blood samples in the
first 3 months after transplantation (2D)
 The utility of monitoring mycophenolic acid (MPA)
C0 levels is uncertain (2D)
 Sirolimus should be monitored by the C0 trough
level (2C)
Guideline 3.14 – KTR: prescribing and the use of generic
agents
We suggest that generic immunosuppression com-
pounds should not be used unless they have been shown
to be bioequivalent and approved by the European
Agency for the Evaluation of Medicinal Products (2D)
Guideline 3.15 – KTR: prescribing and the use of generic
agents
We suggest that KTRs should be made aware of the exist-
ence of generics and the importance of not switching
between preparations without appropriate supervision (2D)
Guideline 3.16 – KTR: prescribing and the use of generic
agents
We suggest that drugs should be prescribed by brand name
(whether branded or generic drugs are prescribed) (2D)
Guideline 3.17 – KTR: prescribing and the use of generic
agents
We suggest that KTRs should be closely monitored after
switching between generic preparations until a new
steady state is established (2D)
Kidney Transplant Recipient: acute rejection
(Guidelines 4.1–4.12)
Guideline 4.1 – KTR: diagnosis of acute rejection
We recommend that a transplant renal biopsy should be
carried out before treating an acute rejection episode un-
less this will substantially delay treatment or pose a sig-
nificant risk to the patient (1C)
Guideline 4.2 – KTR: diagnosis of acute rejection
We suggest that two cores of renal tissue should be ob-
tained at transplant biopsy since this will increase the
sensitivity of the investigation (2C)
Guideline 4.3 – KTR: diagnosis of acute rejection
We suggest that a 16 gauge automated core biopsy needle
is used where possible to provide the best compromise
between diagnostic usefulness and patient tolerance of the
procedure (1C)
Guideline 4.4 – KTR: diagnosis of acute rejection
We recommend that a protocol transplant renal biopsy,
defined as a biopsy performed in a stable graft without
clinical evidence of acute rejection, be considered in the
setting of persisting delayed graft function (1C)
Guideline 4.5 – KTR: diagnosis of acute rejection
We recommend that routine C4d and SV40 staining
should be performed upon transplant biopsies to address
other causes of graft dysfunction (2C)
Guideline 4.6 – KTR: diagnosis of acute rejection
We suggest that a serum sample be sent at the time of
renal biopsy (for graft dysfunction) to look for human
leucocyte antigen (HLA)-specific antibodies (2C)
Guideline 4.7 – KTR: treatment of acute rejection
We suggest that borderline acute cellular rejection
should be treated in the context of acute graft dysfunc-
tion (2D)
Guideline 4.8 – KTR: treatment of acute rejection
We recommend that high dose intravenous corticoste-
roids should be the first line treatment for acute cellular
rejection (1D)
Guideline 4.9 – KTR: treatment of acute rejection
We suggest that maintenance steroids should be added
or restarted in steroid-free patients undergoing acute re-
jection of any type (2D)
Guideline 4.10 – KTR: treatment of acute rejection
We suggest that lymphocyte depleting agents may be
considered for refractory acute cellular rejection or
aggressive vascular cellular rejection (i.e. Banff category
4 Type II and III) (2C)
Guideline 4.11.1 – KTR: treatment of acute rejection
We suggest that antibody mediated rejection (AMR)
should be treated with one or more of the following
modalities: steroids; plasma exchange; intravenous im-
munoglobulin; anti-CD20 antibody, lymphocyte-depleting
antibody or bortezomib (2C)
Guideline 4.11.2 -KTR: treatment of acute rejection
We recommend that the British Transplant Society
(BTS) guidelines on antibody incompatible transplant-
ation for management of rejection in the context of anti-
body incompatible transplantation (1A-D)
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Guideline 4.12 – KTR: treatment of acute rejection
We suggest that - after an episode of rejection (unless
associated with low CNI levels) - azathioprine should be
switched to MPA-based immunosuppression, MPA
should be started, or the existing dose of MPA maxi-
mised (2D)
Kidney Transplant Recipient: chronic allograft injury
(Guidelines 5.1–5.7)
Guideline 5.1 – KTR: diagnosis of chronic allograft injury
We recommend that early identification of graft injury is
desirable to maximise the potential for intervention. A
proactive and systematic approach should employed to
manage graft dysfunction (1C)
Guideline 5.2 – KTR: detection of chronic allograft injury
We suggest that renal function should be monitored at
each clinic visit by assessment of serum creatinine and
qualitative evaluation of urine protein excretion by dip-
stick, supplemented by spot protein:creatinine ratio
(PCR) or albumin:creatinine ratio (ACR) if positive (2C)
Guideline 5.3 – KTR: diagnosis of chronic allograft injury
We suggest that renal biopsy is the optimal investigation
for parenchymal causes of graft dysfunction where the
cause is uncertain (2C)
Guideline 5.4 – KTR: diagnosis of chronic allograft injury
We suggest that renal biopsies in patients with chronic-
ally deteriorating function should be stained for C4d and
SV40 (2C)
Guideline 5.5 – KTR: diagnosis of chronic allograft injury
We suggest that a serum sample should be sent at the
time of renal biopsy (for graft dysfunction) to look for
HLA-specific antibodies (2C)
Guideline 5.6 – KTR: treatment of chronic allograft injury
We suggest that chronic allograft injury should be
treated:
 By withdrawal of calcineurin inhibitors if there is
histological evidence of CNI toxicity or non-specific
interstitial fibrosis and tubular atrophy (2C)
 By intensification of immunosuppression if there is
evidence of ongoing immune injury (cellular
rejection and/or humoral rejection) (2C)
 In a similar fashion to other patients with chronic
kidney disease (CKD), following similar preventative
strategies and with timely referral to low clearance
services (2D)
Guideline 5.7 – KTR: renal biopsy in chronic allograft injury
We suggest that a renal transplant biopsy is indicated:
 If there is a persistent unexplained elevation of
creatinine or failure to return to baseline after an
episode of biopsy proven acute rejection (BPAR) (1C)
 Every 7–10 days during delayed graft function
(DGF) (2C)
 If expected renal function is not achieved within 4–8
weeks (2D)
 If sustained new onset proteinuria develops (PCR
>50 mg/mmol or ACR >35 mg/mmol) (2C)
Kidney Transplant Recipient: cardiovascular disease and
lifestyle (Guidelines 6.1–6.6)
Guideline 6.1 – KTR: hypertension
We suggest that the management of hypertension take
into account that:
 Blood pressure should be recorded at each clinic
visit (1C)
 Clinic blood pressure should be <140/90 mmHg in
clinic (130/80 mmHg if PCR >50 or ACR >35) (2C)
 Home blood pressure recordings and 24-h ambulatory
recordings may be helpful in some instances but lower
BP targets should then be set (home and or ambula-
tory daytime measures <135/80 mmHg) (2D)
 There is no evidence that any antihypertensive agent
is better than any other and effort should be focused
on achieving absolute blood pressure control rather
than the use of individual agents (2D)
 Inhibitors of the renin-angiotensin system may be
more effective in the minimisation of proteinuria but
should be used with caution in the first 3 months
post-transplant (2C)
 Resistant hypertension may be due to transplant
renal artery stenosis and should be investigated
according to local practice (2D)
Guideline 6.2 – KTR: dyslipidaemia
We suggest that the management of dyslipidaemia take
into account that:
 Fasting lipid levels should be measured on an annual
basis in renal transplant recipients (2C)
 Treatment targets should be the same as in the
general population (2C)
 KTRs at increased primary or secondary
cardiovascular risk receive statin therapy to reduce
the risk of coronary artery disease (2C)
 The choice and dose of statin should take into
account concurrent immunosuppression. High dose
simvastatin (≥40 mg daily) should be avoided in
conjunction with ciclosporin and/calcium channel
antagonists (2D)
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Guideline 6.3 – KTR: diabetes mellitus
We suggest that the detection and treatment of diabetes
should consider:
 Screening for the development of post-transplant
diabetes mellitus (PTDM) by dipstick urinalysis and
measurement of blood sugar level at each clinic visit
(2C)
 Post-transplant immunosuppression should take into
account risk factors for the development of diabetes
(2C)
 The diagnosis of PTDM is made based onWHO
criteria for the diagnosis of diabetes mellitus based
on fasting or random blood, serum glycated
haemoglobin (HBA1c) or oral glucose tolerance
testing (1C)
 A diagnosis of PTDM is made once patients are
established on stable maintenance
immunosuppression (2D)
 Post-transplant diabetes should be managed in
collaboration with specialists in diabetic medicine
(2D)
 All units should have a protocol for the
management of post-transplant diabetes (2C)
 KTR with diabetes (either prior to transplantation or
PTDM) should undergo screening for diabetic
complications (retinal screening, foot care,
neuropathy) in line with guidelines for non KTR
patients with diabetes (2D)
Guideline 6.4 – KTR: ischaemic heart disease
We suggest that KTRs receive standard treatment for is-
chaemic heart disease, including thrombolysis, revascu-
larisation, and secondary prevention (2C)
Guideline 6.5 – KTR: smoking cessation
We recommend that smoking should be strongly dis-
couraged in transplant recipients (see guideline 6.4) (1A)
Guideline 6.6 – KTR: lifestyle measures
We suggest that advice on healthy lifestyle forms a rou-
tine part of post-transplant care:
 Maintenance of a healthy diet should be encouraged
(2C)
 An ideal weight should be targeted (body mass
index (BMI) ≤25 kg/m2) (2C)
 Weight management services should be available (2C)
 We suggest that KTRs participate in physical activity
at a level similar to that recommended to age and
co-morbidity matched counterparts from the general
population (2D)
 Alcohol consumption should be within national
guidelines (2D)
 Recreational drug use should be avoided (2D)
 The use of over-the-counter medications (without
discussion with clinical staff ) and non-proprietary
medications (e.g. herbal medicines) should be
discouraged (2D)
Kidney Transplant Recipient: neoplasia (Guidelines 7.1–7.4)
Guideline 7.1 – KTR: screening for cancer
We suggest that the organisation of screening for
neoplasia in KTRs take into account:
 Screening should be similar to the general
population for cervical, breast, colon and prostate
cancer (2C)
 Screening is not recommended for renal cell
carcinoma (2C)
 Patient education pre and post transplantation (1C)
 Patients should be aware of malignancy risk and
encouraged to report symptoms which may
represent de novo malignancy (e.g. breast or
testicular lumps) (2D)
 Skin surveillance by a healthcare professional at least
biannually up to 5 years post-transplant and annu-
ally from 5 years post-transplant (2C)
 Patients with cirrhosis should undergo an annual
hepatic ultrasound and determination of serum
alpha feto-protein (2C)
Guideline 7.2 – KTR: Non-melanoma skin cancer (NMSC)
We recommend that KTRs should be educated about
the adverse effects of sun exposure (1C)
Guideline 7.3 – KTR: Non-melanoma skin cancer
We suggest that KTRs that an individualised assessment
of hazard should be made according to risk factors (2C)
Guideline 7.4 – KTR: Non-melanoma skin cancer
We recommend that patients should be encouraged to
cover their skin in direct sunlight and to use total
sunblock (Sun Protection Factor ≥50) (1D)
Guideline 7.5 – KTR: Non-melanoma skin cancer
We suggest that self-examination should be encouraged
with guidance provided. This should be supplemented
by at least biannual review by a trained healthcare pro-
fessional up to 5 years post-transplant and annual review
from 5 years (2C)
Guideline 7.6 – KTR: Non-melanoma skin cancer
We suggest that the prescription of acitretin as chemo-
prophylaxis be considered in those with ≥2 previous
NMSC if there are no contraindications (2B)
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Guideline 7.7 – KTR: immunosuppression in cancers
We suggest that immunosuppression should be reduced
if neoplasia develops (2C)
Guideline 7.8 – KTR: immunosuppression in cancers
We suggest that mammalian target of rapamycin inhibi-
tors (m-TORi) are considered as alternative immuno-
suppressive agents in KTRs who develop de novo
malignancy (2C)
Guideline 7.9 – KTR: immunosuppression in Kaposi sarcoma
We suggest that m-TORs have specific anti-tumour
effects in Kaposi sarcoma (2C)
Kidney Transplant Recipient: infection
complications (Guidelines 8.1–8.9)
Guideline 8.1 – KTR: vaccination
Guideline 8.1.1 – KTR: vaccination
We recommend that KTRs:
 Should be vaccinated with inactivated viruses as per
the normal population (1D)
 Should receive annual influenza vaccination unless
contraindicated (1C)
Guideline 8.1.2 – KTR: vaccination
We suggest that KTRs:
 Should have hepatitis B surface antibody (HBsAb)
levels rechecked annually and be revaccinated if
antibody titres fall below 10 mIU/mL (2D)
 Should not receive live attenuated vaccines (2C)
 Should receive pneumococcal vaccine and a booster
every five years (2D)
Guideline 8.2 – KTR: cytomegalovirus (CMV) disease
Guideline 8.2.1 – KTR: prophylaxis and treatment of CMV
disease
We recommend:
 Prophylaxis should be continued for 3–6 months,
until immunosuppression has been reduced to long-
term maintenance level (1B)
 Treatment should be administered for 6 weeks after
treatment with a TDA (1C)
Guideline 8.2.2 – KTR: prophylaxis and treatment of CMV
disease
We suggest:
 All transplant units should be able to measure CMV
serological status and quantify viral load (2D)
 Donor and recipient CMV status should be
recorded at the time of transplantation (2D)
 Each unit should have a written protocolised CMV
strategy based on prophylaxis or pre-emptive
therapy (2D)
 For the treatment of mild and moderate CMV
disease, oral valganciclovir and intravenous
ganciclovir are of equivalent efficacy (2C)
 The first line treatment of life-threatening CMV
disease is intravenous ganciclovir (2D)
 Treatment duration should be determined by
monitoring viral load (2C)
Guideline 8.3 – KTR: Epstein Barr Virus (EBV) infection
Guideline 8.3.1 – KTR: EBV infection
We recommend that immunosuppression should be
reduced or stopped following the development of post
transplant lymphoproliferative disease (PTLD) (1C)
Guideline 8.3.2 – KTR: EBV infection
We suggest:
 Both donor and recipient should have their EBV
serology recorded at the time of transplantation
(2D)
 All high risk (D+/R−) patients (including adults)
should have EBV viral load measured immediately
after transplantation, monthly for 6 months, and 3
monthly to 1 year (2C)
 EBV viral load should be monitored after the
treatment of rejection (2C)
 Total immunosuppression should be reduced when
EBV titres rise significantly (2C)
Guideline 8.4 – KTR: Varicella Zoster Virus (VZV) infection
Guideline 8.4.1 – KTR: VZV infection
We recommend:
 Primary infection (chickenpox) should be treated
with intravenous aciclovir or oral valaciclovir until
the lesions scab over (1C)
 Uncomplicated shingles should be treated with oral
acyclovir or valaciclovir until the lesions scab over
(1D)
 Disseminated (>2 dermatomes), ocular or invasive
shingles should be treated with intravenous aciclovir
until the lesions scab over, together with a reduction
in immunosuppression (1B)
 Varicella-susceptible KTRs (i.e. VZV IgG negative)
with primary exposure to VZV should receive
intravenous immunoglobulin, ideally within
96 hours, but up to a maximum of 10 days following
exposure. If unavailable or after 10 days, oral
aciclovir should be prescribed for seven days (1D)
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Guideline 8.4.2 – KTR: VZV infection
We suggest:
 Patients on the waiting list who are VZV IgG
negative should be vaccinated prior to
transplantation (2D)
 Immunosuppression should be reduced during
primary infection (2D)
Guideline 8.5 – KTR: Herpes Simplex Virus (HSV) infection
Guideline 8.5.1 – KTR: HSV infection
We recommend:
 Superficial HSV infection should be treated with
appropriate oral agents until the lesions have
resolved (1D)
 Systemic HSV infections should be treated with
intravenous aciclovir and a reduction in
immunosuppression until a response occurs and oral
medication should be continued for at least 14 days
(1C)
Guideline 8.5.2 – KTR: HSV infection
We suggest that KTRs suffering frequent recurrent HSV
infection should consider oral prophylaxis (2D)
Guideline 8.6 – KTR: BK virus (BKV) nephropathy
Guideline 8.6.1 – KTR: BK nephropathy
We recommend that confirmed BK nephropathy should
be treated by reduction in immunosuppression (1D)
Guideline 8.6.2 – KTR: BK nephropathy
We suggest:
 Screening should also be carried out when renal
function deteriorates in an unexplained fashion (2D)
 KTRs should be screened for BKV viral load or by
performing urine microscopy for decoy cells or by
polymerase chain reaction (PCR) on urine or serum
(2C)
 Suspected BK nephropathy should be confirmed by
renal biopsy, which should be stained for SV40. Two
cores containing medullary tissue should ideally be
examined (2D)
 Immunosuppression should be reduced when the
serum BKV load exceeds 104 copies/ml (2C)
 There is no established specific treatment for BK
nephropathy (2D)
 Re-transplantation can safely be considered in
patients who have BK nephropathy diagnosed in an
earlier graft (2C)
Guideline 8.7 – KTR: pneumocystis jirovecii infection -
treatment and prophylaxis
We suggest:
 All patients with confirmation (microscopy or PCR)
of Pneumocystis jirovecii in respiratory secretions
should be treated for 14 to 21 days with co-
trimoxazole orally or intravenously (15-20 mg/kg in
three or four divided doses) (2B)
 Patients with contraindications to treatment with
co-trimoxazole should receive pentamidine (4 mg/
kg/day intravenously) (2B)
 Adjunctive glucocorticoid therapy may be
considered in patients with severe disease (2D)
 All patients should receive 3–6 months of treatment
with co-trimoxazole 480 mg daily for Pneumocystis
jirovecii prophylaxis following renal transplantation
(1B)
Guideline 8.8 – KTR: post-transplant infection prophylaxis
We suggest:
 All patients should receive 3–6 months of treatment
with co-trimoxazole 480 mg daily (1B)
 Oral antifungal prophylaxis should be administered
for 1 week after transplantation (2C)
 In selected patients, prophylaxis against
mycobacterium tuberculosis with daily isoniazid
(supplemented with pyridoxine) should be instituted
for 6 months after transplantation (2C)
Guideline 8.9 – KTR: Hepatitis E Virus (HEV)
We recommend that Hepatitis E Virus (HEV)-screened
blood components should be given to all KTR (1C)
Kidney Transplant Recipient: bone and joint disease
(Guidelines 9.1–9.4)
Guideline 9.1 – KTR: osteoporosis
We suggest:
 KTRs suffering from osteoporosis or at high
potential risk should be considered for steroid-
avoiding immunosuppression (2D)
 KTRs on long-term steroids or at high risk for
osteoporosis should undergo DEXA scanning if
eGFR >30 mL/min/1.73 m2 (2D)
 Treatment should be according to the Royal College
of Physicians (RCP) guidelines for steroid-induced
osteoporosis (2D)
Guideline 9.2 – KTR: tertiary hyperparathyroidism
We suggest:
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 Severe hyperparathyroidism should be treated prior
to transplantation (2D)
 Cinacalcet can be used in KTR (2C)
 Treatment should be the same as for other patients
with CKD (2D)
Guideline 9.3 – KTR: gout
Guideline 9.3.1 – KTR: treatment of gout
 We recommend that neither allopurinol nor
febuxostat should be administered with azathioprine
(1C)
Guideline 9.3.2 – KTR: treatment of gout
We suggest:
 Hyperuricaemia should be treated when associated
with gout, tophi or uric acid stones (2D)
 Non-steroidal anti-inflammatory drugs (NSAIDs)
should be avoided in KTRs (2D)
 Acute gout may be treated with brief a course of
oral prednisolone. (2D)
 Colchicine is an effective treatment for gout in KTR
(2D)
Guideline 9.4 – KTR: calcineurin inhibitor bone pain
We suggest:
 Reduction or withdrawal of CNIs should be
considered in KTRs with intractable bone pain (2D)
 Dihydropyridine calcium antagonists also may be
beneficial (2D)
Kidney Transplant Recipient (KTR): haematological
complications (Guidelines 10.1–10.3)
Guideline 10.1 – KTR: anaemia
We suggest that chronic anaemia should be managed in
the same way as other patients with CKD (2D)
Guideline 10.2 – KTR: polycythaemia
We recommend that initial treatment should be with
angiotensin converting enzyme inhibitors (ACEIs) or
angiotensin receptor blockers (ARBs) (1C)
Guideline 10.3 – KTR: polycythaemia
We suggest:
 Haemoglobin levels should be monitored at every
clinic visit (2D)
 Treatment should be initiated if the haematocrit or
packed cell volume exceeds 52% in men and 49% in
women (2D)
 Venesection may be used in refractory cases.(2D)
Kidney Transplant Recipient (KTR): reproductive issues
(Guidelines 11.1–11.5)
Guideline 11.1 – KTR: conception and contraception
(female)
We recommend that MPA-containing immunosuppres-
sant drugs should be stopped prior to conception and
replaced appropriately (1A)
Guideline 11.2 – KTR: conception and contraception
(female)
We suggest:
 KTRs should wait for 1 year after transplant and
have stable function before attempting conception
(2C)
 Counselling regarding fertility and reproduction
should be offered to female KTRs and their partners
either prior to transplantation or soon afterwards
(2D)
 m-TORi should be stopped prior to conception and
replaced as appropriate (2D)
 Pregnancy should be jointly managed with an
Obstetrics department with experience of care of
KTR (2D)
 KTRs receive aspirin 75 mg daily to reduce the risk
of pre-eclampsia from 12 weeks gestation until birth
of the baby unless there are contraindications (2C)
 The risks and benefits of breastfeeding should be
discussed (2D)
 Contraception advice should be similar to the
general population (2D)
Guideline 11.3 – KTR: conception and contraception (male)
We recommend:
 Male KTRs are advised that MPA containing
compounds have theoretical teratogenic potential in
men taking these agents (1D)
 KTRs should be advised that m-TORi reduce the
male sperm count and counselled accordingly. (1C)
Guideline 11.4 – KTR: conception and contraception (male)
We suggest:
 All immunosuppressive drugs other than m-TORi
can be used in male KTRs. Advice for MPA is as
Guideline 11.3 (2D)
 The decision to continue MPA containing
compounds in a male KTR wishing to conceive
should balance the risk of theoretical teratogenicity
against the risk of rejection on changing from MPA
to azathioprine (2D)
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 Men on m-TORi who wish to conceive should
discontinue these agents prior to conception and
replace them as appropriate (2D)
 Men who wish to maintain fertility should avoid m-
TORi or bank sperm prior to starting these drugs
(2D)
Guideline 11.5 – KTR: sexual dysfunction
We suggest:
 Specific enquiry should be made regarding sexual
dysfunction, preferably at an annual review clinic (2D)
 Care pathways for dealing with sexual dysfunction
should be established (2D)
 Close liaison with local andrology service is
recommended (2D)
 Sildenafil is safe and effective in male KTR not
taking nitrates (2D)
Summary of audit measures for the post-
operative care of the kidney transplant recipient
 Proportion of blood results available for review, and
reviewed, within 24 h
 Proportion of units with a written follow-up sched-
ule available to all staff and patients
 Percentage of patients accessing their results
through Renal Patient View
 Percentage of total patients assessed in an annual
review clinic
 Recording “Did Not Attend” (DNA) rates for all
patients
 Recording sub-therapeutic drug levels. Measuring
within-patient variability of CNI levels
 Percentage of total patients receiving induction with
ILRAs and TDAs
 Percentage of de novo KTRs receiving tacrolimus
 Percentage of de novo KTRs receiving MPA based
immunosuppression
 Percentage of de novo KTRs receiving corticosteroid
maintenance therapy
 Use of generic agents
 Severity of biopsy proven acute rejection (BPAR)
recorded by Banff criteria
 Percentage of KTRs with BPAR in first 3 months
and first 12 months
 Percentage of KTRs requiring TDAs to treat
rejection in first year
 Complication rates after renal transplant biopsy
 The percentage of KTRs with BPAR in first
3 months and the first 12 months
 The percentage of KTRs with a donor specific HLA
antibody at the time of biopsy
 The percentage of KTRs with positive C4d staining
on biopsy
 Proportion of patients receiving a target blood
pressure of 140/90 mmHg or 130/80 mmHg in the
presence of proteinuria (PCR >100 mg/mmol or
ACR >70 mg/mmol)
 Proportion of patients with proteinuria assessed by
dipstix and, if present, quantified at each clinic visit
 Proportion of renal transplant recipients with an
annual fasting lipid profile
 Proportion of RTR taking statins (including the type
of statin) for primary and secondary prevention of
premature cardiovascular disease
 Proportion of patients on other lipid lowering agents
 Proportion of patients achieving dyslipidaemia
targets
 Incidence of post-transplant diabetes mellitus
(PTDM) at 3 months and at annual intervals
thereafter
 Proportion of patients who require insulin, and in
whom remedial action is undertaken – minimisation
of steroids and switching of CNIs
 The proportion of patients with PTDM enrolled in
screening for extra-renal complications of PTDM
 Proportion of patients with ischaemic heart disease
 Proportion of patients suffering myocardial
infarction
 Proportion of patients undergoing primary
revascularisation
 Proportion of patients receiving secondary
prevention with a statin, anti-platelet agents and
renin angiotensin system (RAS) blockers
 Proportion of KTRs who smoke
 Proportion of cigarette smoking KTRs who have
been given formal advice or offered help with
cessation
 Proportion of patients who are obese (BMI > 30 kg/m2)
 Proportion of patients having screening procedures
for neoplasia at the annual review clinic
 Incidence of CMV disease
 Rate of EBV infection and PTLD
 Completeness of records for EBV donor and
recipient serology
 Rates of primary VZV and shingles infection
 Completeness of records for VZV recipient serology
 Rates and outcomes of HSV infections
 Rates of BK viral infection in screening tests
 Rates and outcomes of BK nephropathy
 Frequency of bisphosphonate use
 Incidence of fractures
 Incidence of hyperparathyroidism
 Incidence of parathyroidectomy
 Use of cinacalcet
 Frequency of hyperuricaemia and gout
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 Prevalence of anaemia
 Prevalence of polycythaemia
 Pregnancy rates and outcomes
 Prevalence of sexual dysfunction
Rationale for clinical practice guidelines for post-
operative care of the kidney transplant recipient
Kidney Transplant Recipient (KTR): organisation of
outpatient follow-up (Guidelines 1.1 – 1.4)
Guideline 1.1 – KTR: clinic infrastructure
We suggest that the following infrastructure should be
in place for KTR follow up (2D)
 A consultant-level health care professional should be
available for every transplant clinic
 KTRs should be reviewed in a dedicated outpatient
area
 The results of blood tests (including drug levels if
possible) should be available within 24 h.
 A formal mechanism should exist for results review
by health care professionals within 24 h of a clinic
appointment
 There should be access to a multidisciplinary renal
team including pharmacist, dietician, social worker
and psychologist
 Patient care should be planned along principles set
out in the National Service Framework and “Kidney
Health Delivering Excellence”
Audit Measure The proportion of blood results avail-
able for review, and reviewed, within 24 h
Rationale All KTRs should have ready access to a senior
clinical opinion and a senior clinician should be available
at renal transplant clinics. In some centres this may be a
consultant-level nurse, in others a medical or surgical
consultant. The exact type of healthcare professional is
not important but KTRs and junior staff should have ac-
cess to an individual with appropriate knowledge and ex-
perience. This will also benefit the training of junior
medical staff. A dedicated outpatient area is beneficial as
it provides a familiar environment and staff experienced
in the management of patients on renal replacement
therapy.
Prompt availability and formal review of test results is
desirable since most complications can be resolved more
easily if recognised at an early stage, particularly in the
first few weeks after renal transplantation. It is recom-
mended that patient care is carried out according to the
principles laid out in the Department of Health (DoH)
leaflet, “Achieving Excellence in Kidney Care [47] and
the report by Kidney Research UK “Kidney Health Deliv-
ering Excellence” [211].
Guideline 1.2 – KTR: clinic frequency
We suggest that uncomplicated patients, in genral, may
be reviewed progressively less frequently in clinic (2C)
 2–3 times weekly for the first month after
transplantation
 1–2 times weekly for months 2–3
 Every 2–4 weeks for months 4–6
 Every 4–6 weeks for months 6–12
 3–6 monthly thereafter
Audit Measure Proportion of units with a written
follow-up schedule available to all staff and patients
Rationale Freedom from regular hospital attendance is
an important benefit of renal transplantation, balanced
against the risks and prevention of complications. These
risks (especially of surgical complications) are highest in
the immediate postoperative period and during the first
few weeks following hospital discharge, when the burden
of immunosuppression is greatest. For typical patients
monitoring should therefore be most frequent during
this period and then diminish with time. The use of vir-
tual renal clinics should be explored as a complementary
form of KTR review as it might be more convenient for
some patients.
Guideline 1.3 – KTR: patient access
We suggest that all patients should have ready access to
support services and results (2C)
 All patients should have on-line access to their re-
sults via the “Renal Patient View” service if they
wish
 All patients should have open access to the renal
transplant outpatient service and have an established
point of contact for enquiries
 Patient information should be available in both
written and electronic formats
Audit Measure Percentage of patients accessing their
results through Renal Patient View
Rationale Patients should be encouraged to take an ac-
tive role in their own care according to principles em-
bodied in the National Service Framework [47]. Interest
in their own blood results should be welcomed and
KTRs should be encouraged to use Patient View
(https://www.patientview.org/#/; formerly known as
Renal Patient View). Patient education is a crucial elem-
ent in the success of renal transplantation and easy ac-
cess to information should be provided for all patients in
different formats (e.g. paper-based and electronic).
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Guideline 1.4 – KTR: chronic transplant care review
We suggest that a detailed review should be performed
annually post-operatively (2C)
 A process should exist for patient review on an
annual basis in a different format of clinic according
to the “Care plan model”
 This should be a patient-centred clinic, facilitated by
a health care professional
 It should address concerns in medical, social,
psychological and sexual domains
 Open access to a renal dietician, social worker,
specialist renal pharmacist and/or psychologist
should be readily available from this clinic
 This process should proceed in parallel with formal
medical review
Audit Measure Percentage of total patients assessed in
an annual review clinic
Rationale Since KTRs experience considerable late
morbidity which is unlikely to be managed properly in a
traditional clinical setting (e.g. skin lesions, sexual dys-
function and psychological morbidity) it seems sensible to
facilitate periodic follow up in a different and more holis-
tic environment [173, 193].
Kidney Transplant Recipient (KTR): Non-adherence
(Guideline 2.1)
Guideline 2.1 – KTR: recognising non-adherence
We suggest that it is important to prevent and detect
non-adherence in kidney transplant recipients (2C)
 Factors associated with non-adherence should be
identified
 An established interventional pathway should be in
place for those at high risk of or with proven non-
adherence
 Pathways should be in place for paediatric KTRs in
transition and for adolescent KTRs
Audit Measures
 Recording “Did Not Attend” (DNA) rates for all
patients
 Recording sub-therapeutic drug levels
 Measuring within-patient variability of CNI levels
Rationale Non-adherence with immunosuppressive
medication is an important factor in graft loss and up to
a third of patients report regularly missing tablets [28,
153, 166, 206]. One Dutch study described self-reported
non-adherence rates of 17% at 6 weeks after transplant-
ation rising to 27% by 6 months [134]. Clinical parame-
ters associated with non-adherence are well recognised
and should be used to assessing risk e.g. erratic or low
immunosuppression levels, clinic non-attendance, psy-
chiatric illness, low belief in the need for medication,
adolescence and early adulthood [153, 166, 206]. The pa-
tient and/or their carer should be fully engaged in iden-
tifying reasons for and strategies to address non-
adherence. High within-patient variability of CNI levels
has also been shown to be associated with poor graft
outcomes and can readily be monitored in the clinic [99,
184, 214]. It remains to be proven whether there is a
prospective intervention in such patients that can im-
prove outcomes.
Kidney Transplant Recipient (KTR): immunosuppressive
treatment (Guidelines 3.1 – 3.17)
General concepts
The starting point for renal transplantation is compari-
son with other forms of renal replacement therapy
(RRT). Renal transplantation provides a better quality of
life, an increased sense of well-being and a longer life
span when compared to other forms of RRT. Therefore
minor differences in clinical outcome between different
immunosuppressive regimes should be placed in context
with the much greater difference in outcome between
transplantation and other forms of RRT, for those fit
enough to be wait listed (approximately 30% of those
with end stage renal disease).
Almost all renal transplants are allogeneic (i.e. not
from identical twins) and will provoke a powerful im-
munological rejection response in the recipient. Rejec-
tion will destroy renal tissue and so the primary aim of
immunosuppression is to avoid rejection. In general,
more potent immunosuppressive regimes will reduce the
risk of all forms of rejection but at the expense of
increased side effects. Side effects comprise generic
immunosuppressive side effects (e.g. increased risk of
infection and malignancy) or those specific to the par-
ticular drug used (e.g. gingival hypertrophy with
ciclosporin).
Immunosuppressive management may be divided
into three phases – induction, early (<3–6 months
post-transplant), and late (>3–6 months). More inten-
sive immunosuppression is required in the early post-
operative period to prevent acute rejection episodes,
while long-term immunosuppression should balance
the risk of rejection against the adverse effects of
immunosuppressive therapy. Effective immunosup-
pression is best achieved by combination therapy that
minimises the side effects of individual agents. Overall,
the aim of immunosuppression is to maximise patient
and graft survival following transplantation and to
maximise the quality of life and economic benefits of
transplantation.
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When planning immunosuppressive treatment, it is
essential to consider the risks to the recipient. The risks
of immunosuppressive therapy are largely predictable
and should be balanced against the risk of harm to the
individual patient from under-immunosuppression and
resulting rejection, and the benefits of a well-functioning
transplant. The assessment of risk is imprecise but
Table 1 illustrates some broad principles. Many trans-
plant units employ such risk stratification but there is
very little evidence to support such an approach since
most studies have excluded high-risk patients.
For the purpose of these guidelines, immunosuppres-
sion has been broadly divided into induction and
maintenance phases; the maintenance phase can be
further divided into early and late. While the distinc-
tion between these periods is largely arbitrary, here the
induction period is considered as the peri-transplant
period, the early maintenance period is the 3–6 month
period after transplantation when immunosuppression
is tapered, and the late maintenance phase is the
period beyond 3–6 months when immunosuppression
has been tapered to long-term levels. It is recognised
that the renal allograft is more immunogenic during
the early post-transplant period and that more potent
immunosuppression is therefore required to prevent
rejection. In the later maintenance phase the allograft
becomes less immunogenic and more consideration
can be given to the minimisation of side effects from
immunosuppression.
Immunosuppressive strategies may be pre-emptive or
reactive. For example, steroid avoidance is pursued by
some units with the objective of avoiding steroid-related
side effects. It also permits the widespread usage of ta-
crolimus with a reduced risk of post-transplant diabetes
mellitus (PTDM). Other units adopt a strategy of dual
or lower dose triple immunosuppressive drug therapy.
When considering the published evidence, it is essen-
tial to look at long-term outcome data. However, long-
term data from adequately powered clinical trials are fre-
quently not available and the best evidence comes from
large registries with their inherent limitations of data
collection and bias. It is also important to focus on
intention-to-treat analysis to limit the bias associated
with intolerance of therapy, which is common in this
population.
Guideline 3.1 – KTR: immunosuppression regimen
We recommend that the patient and/or carer should be
engaged in the decisions around selection of induction
agent and maintenance immunosuppression (1D)
Rationale Immunosuppressive therapy for kidney trans-
plantation has a wide and potentially serious side effect
profile, including increased risk of cancer, cardiovascular
disease and infection. Engagement with patients about
anticipated short and long-term side effects of immuno-
suppressive therapy allows discussions to reassure about
some anticipated side effects, whilst informing about
others. This may aid adherence with therapy and allay
untoward concerns about medication side effects.
Table 1 Risk stratification for selection of immunosuppression in kidney transplantation
Risk Type Low Medium High Possible Strategy
Immunological 0-DR mismatch
First graft
Unsensitised
Recipient >60
1-DR mismatch
Afro-Caribbean recipient
Historical DSAs
NDSAs
DGF
Older donor
[45]
2-DR mismatch
Previous early immunological
graft loss
DSAs
ABO-incompatible
Sensitised (high CRF/PRA)
Preoperative anti-ATIIR Abs
[117]
Increase total immunosuppressive load
Metabolic Low BMI
Age <40
Normal
pre-Tx GTT
Positive family history
ADPKD
Impaired GT
BMI >35
HCV positive
Age >60
Previous CVD
Race
Avoid/minimise
steroids and tacrolimus
Neoplastic Age <40 Pre-malignant lesion Previous cancer
Hereditary syndrome e.g. VHL
Consider low immunosuppression load
or sirolimus
Ischaemia-reperfusion
injury
Living donor
Deceased donor <40
CIT >12 h
Donor aged 50–60
DCD
CIT > 24 h
Extended criteria donor
Reduce CNI exposure
Non-adherence Poor RRT compliance
Age <20
Transition from paediatric
to adult
Education
Simple drug regime
alemtuzumab or belatacept
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Guideline 3.1 – KTR: induction immunosuppression
We recommend induction therapy should take into
account the following:
 Immunosuppressive drugs should be started before
or at the time of renal transplantation (1B)
 Induction therapy with biological agents should be
administered to all KTRs (1B). In patients at low
immunological risk this will generally involve an
interleukin-2 receptor antagonist (IL2-RA). Recipients
at higher immunological risk may be considered for
T-cell (lymphocyte) Depleting Antibodies (TDAs; e.g.
anti-lymphocyte preparations [antithymocyte globulin
(ATG) or alemtuzumab])
 Induction therapy with TDAs may also be useful for
lower immunological risk patients with the intention
of either steroid or CNI avoidance (1C)
Guideline 3.2 – KTR: induction immunosuppression
We suggest that a CNI should be started at the time of
transplantation and not delayed until the graft is func-
tioning (2C)
Audit Measure Percentage of total patients receiving
induction with ILRAs and TDAs
Rationale Following allogeneic renal transplant there is
an intense period of immunological activity whereby re-
cipient lymphocytes respond to allogeneic material. In-
duction therapy aims to minimise this response and the
risk of early graft rejection at a time when oral agents
may not have reached effective concentrations.
There is good evidence that IL2-RAs reduce the risk
of early rejection when compared to placebo, although
there is no definitive evidence of improved graft survival
at 3 years, nor are there trials of adequate statistical
power to answer the question of long-term benefits.
There is, however, some evidence from registry data to
suggest that the lower rejection rates might translate
into better graft survival [121]. Pharmacoeconomic ana-
lysis has shown that these agents are cost effective in the
early post-transplant period, and this is embodied in Na-
tional Institute for Clinical Excellence (NICE) guidelines
(https://www.nice.org.uk/guidance/ta85) [165].
There is moderate evidence that TDAs reduce the risk
of acute rejection in high-risk immunological recipients.
However, this benefit is generally gained at the expense
of increased side effects - in particular, an increased inci-
dence of malignancy, cytopenia and infection. Four ran-
domised controlled trials comparing alemtuzumab to
basiliximab in standard risk patients have consistently
demonstrated reduced rates of acute rejection with
alemtuzumab but longer-term outcomes are still awaited
[30, 70, 73, 225]. However, alemtuzumab has been
associated with increased side effects in most studies
and for most patients it would seem unnecessary other
than as part of a strategy to avoid other drugs, e.g. corti-
costeroids. Anti-thymocyte globulin has been shown to
reduce the incidence of acute rejection in standard risk
KTRs when compared to an IL2RA, but follow up at 10
years did not show any significant clinical differences be-
tween the two groups [120]. A multicentre prospective
RCT compared ATG to IL2RA in high risk KTRs and
demonstrated significantly reduced rejection rates but
no significant difference in 5 year outcomes [80]. Simi-
larly, ATG may reduce acute rejection rates in black
KTRs and reduce the incidence of antibody mediated re-
jection (AMR) and donor-specific antibody production,
but long-term evidence of benefit is lacking [21, 163].
There is limited evidence to suggest that the clinical
profile of alemtuzumab differs from that of other T cell
depleting antibodies, with a lower incidence of post
transplant lymphoproliferative disease (PTLD) [106].
Preliminary evidence suggests that that B lymphocyte
depleting antibodies, such as anti-CD20, (rituximab)
are not suitable as routine induction agents [36, 128].
Rituximab may be useful as induction agent in ABO
incompatible transplantation [122].
Guideline 3.3 – KTR: maintenance immunosuppression
We recommend that maintenance immunosuppression
should normally consist of a calcineurin inhibitor (CNI),
an anti-proliferative agent with or without corticoste-
roids in low and medium immunological risk KTRs (1B)
Guideline 3.4 – KTR: maintenance immunosuppression
We suggest that low-medium dose tacrolimus (trough
target 4-8 ng/ml) is recommended as the CNI of choice
in patients also taking steroids who are low and medium
immunological risk and are not at high risk of develop-
ing post transplant diabetes mellitus (PTDM) (2C)
Guideline 3.5 – KTR: maintenance immunosuppression
We suggest that slow release tacrolimus preparations are
used as second line agents for patients who suffer
intolerable side effects related to peak dose toxicity (2C)
Guideline 3.6 – KTR: maintenance immunosuppression
We suggest that KTRs who are unable to tolerate tacro-
limus or who suffer serious adverse reactions related to
its use be considered for use of second line agents such
as ciclosporin, sirolimus, everolimus, or belatacept (1B)
Guideline 3.7 – KTR: maintenance immunosuppression
We suggest that MPA-based drugs should be the first-
line antiproliferative agent, in preference to azathioprine
except in fertile KTRs who are unwilling to use reliable
contraception (2B)
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Guideline 3.8 – KTR: maintenance immunosuppression
We suggest that mycophenolate mofetil (MMF) and
enteric-coated mycophenolate sodium (Myfortic®) pro-
vide equivalent maintenance immunosuppression (2B)
Guideline 3.9 – KTR: maintenance immunosuppression
We suggest that vigilant steroid avoidance or steroid
withdrawal during the first week after transplantation
can generally be used in low immunological risk kidney
transplant recipients (2B)
Guideline 3.10 – KTR: maintenance immunosuppression
We suggest that minimum target levels for CNIs should
be instituted in uncomplicated renal transplantation
after 3 months (2C)
Guideline 3.11 – KTR: maintenance immunosuppression
We suggest that CNIs should be continued rather than
withdrawn (2B)
Guideline 3.12 – KTR: maintenance immunosuppression
We suggest if steroids are not withdrawn within the first
month then they should be maintained at low dose
(Prednisolone - 5 mg per day or less) (2C)
Audit Measures
 Percentage of de novo KTRs receiving tacrolimus
 Percentage of de novo KTRs receiving MPA-based
immunosuppression
 Percentage of de novo KTRs receiving corticosteroid
as part of maintenance therapy
Rationale Immunosuppressive drugs are generally used
in combination to balance effective total immunosup-
pression with minimisation of drug-specific side ef-
fects. Since the graft is most immunogenic in the early
post-transplant period it is important to use higher
doses of these drugs during this period. Thereafter
dosages and thus blood levels can be reduced to min-
imise the risks of infection and malignancy. Account
should be taken of the immunological risk of the trans-
plant and also the strength of induction therapy, i.e.
KTRs induced with TDAs often require less intensive
maintenance therapy. High, medium and low trough
(C0) levels for tacrolimus are >10, 5–10 and <5 ng/mL
respectively. Comparable C0 levels for ciclosporin are
>200, 100–200 and <100 ng/ml respectively.
It should be acknowledged that the optimal combin-
ation of immunosuppressive agents to obtain the best
long-term outcomes, defined by hard endpoints such as
graft and patient survival, remains elusive. There are a
number of reasons for this:
 short duration of increasingly expensive trials
 convergence of outcomes with many different
regimes for short term surrogate endpoints (e.g.
rejection rates and graft function)
 restrictions on trial recruitment which exclude many
real world patients
In the absence of such data a flexible approach is re-
quired whereby KTRs are stratified by risk and the ma-
jority are started on standard protocols. However,
clinicians must be vigilant and be willing to substitute al-
ternative agents when necessary.
Except for transplants from syngeneic or haploidenti-
cal live donors, it is generally established practice in
renal transplantation to use triple therapy as mainten-
ance, consisting of a CNI, an antiproliferative agent and
corticosteroids. Such regimes have led to the lowest re-
jection rates and are considered the benchmark to which
other regimes are compared. Induction therapy plus
low-dose tacrolimus, mycophenolate mofetil (MMF) and
corticosteroids have produced the lowest rates of acute
rejection, superior graft function, and better graft
survival. There are examples of other regimes for main-
tenance therapy, generally involving avoidance, mini-
misation or withdrawal of either steroids or CNIs. Such
regimes that can produce similar outcomes in selected
patients but there are currently no reliable instruments
to predict which KTRs will benefit.
A large randomised controlled trial (RCT) suggested
that low dose tacrolimus combined with MMF and
steroids with an IL2-RA as induction was superior at
12 months in terms of graft function, graft survival
and acute rejection rate to either standard or low
dose ciclosporin in low immunological risk KTRs [53,
54]. There are concerns over the early nephrotoxic ef-
fects of CNIs but whether these observations extend
to lower doses and levels is unknown. To date, no al-
ternative to CNIs has been shown to improve either
early or late graft outcomes. Favourable outcomes in
this trial [53] were based on tacrolimus levels of 3–
7 ng/mL. More recent data suggest that trough tacro-
limus levels <4.0 ng/mL was associated with higher
levels of rejection in the ‘post-SYMPHONY’ era [65].
Therefore a pragmatic compromise would be to aim
for trough tacrolimus levels of 4-8 ng/mL.
The risk of acute rejection is minimised by early
achievement of target CNI levels and so there is no
reason to delay the initiation of a CNI. Specifically there
is no evidence that delaying the introduction of a CNI
prevents or ameliorates delayed graft function.
Trial evidence demonstrates that tacrolimus reduces
the risk of acute rejection and improves graft survival
during the first year of transplantation compared to
ciclosporin [221]. Protocol biopsy studies also suggest
that subclinical rejection is less prevalent in regimes
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containing tacrolimus as opposed to ciclosporin [179].
However, PTDM is significantly more common with
tacrolimus even accounting for variation in concomi-
tant steroid usage [230]. An RCT comparing tacroli-
mus with ciclosporin (Neoral) in non-diabetic patients
demonstrated significantly higher levels of abnormal-
ities in glucose metabolism with tacrolimus but a non-
significant trend towards worse graft function with
ciclosporin [216]. However, lower blood levels of tacro-
limus minimise the risk of PTDM compared to higher
levels; this has not been fully explored in a trial setting.
It is acknowledged that tacrolimus is associated with a
number of side effects. Some milder side effects relating
to peak levels of the parent compound (e.g. tremor) may
be ameliorated by dose reduction or the use of slow re-
lease formulations of tacrolimus [116]. However, tacroli-
mus may cause disabling side effects in a minority of
patients including posterior reversible encephalopathy
syndrome, haemolytic uraemic syndrome, alopecia and
GI disturbance. In such circumstances it is usually ne-
cessary to switch to a second line agent such as ciclos-
porin, m-TORi or belatacept.
Compared with placebo and azathioprine, mycophe-
nolic acid based compounds, (MMF, mycophenolate
sodium, generic MPA) reduces the risk of acute rejec-
tion [145, 189]. The evidence comparing MPA to pla-
cebo consistently demonstrates lower rates of acute
rejection with MPA but at the expense of increased
bone marrow suppression and increased opportunistic
infection rates. Systemic review of the relevant studies
suggests significantly reduced rejection rates and im-
proved graft survival with MPA compared to azathi-
poprine [219]. Absolute numbers of patients with
gastrointestinal side effects are higher with MMF
though this is not significant. There is limited evidence
that mycophenolate sodium (Myfortic) leads to a re-
duced incidence of gastrointestinal side effects com-
pared to mycophenolate mofetil, albeit in studies
specifically addressing patients with gastrointestinal
side effects, rather that larger studies of KTRs [191].
All mycophenolic acid based compounds are associ-
ated with significant teratogenicity in both women and
men and should not be used in fertile KTRs who are
unwilling to use reliable contraception [146].
Steroids have a well-documented adverse effect pro-
file and there is heightened interest in steroid with-
drawal and avoidance regimes. Whether low dose
prednisolone (e.g. 5 mg daily) is associated with a simi-
lar adverse profile to higher dose regimens is un-
known. Interestingly there is little evidence of an effect
on insulin sensitivity between no steroids and 5 mg
daily [140]. The majority of accumulated trial evidence
in renal transplantation has involved steroid-
containing regimes and there is little information re
steroid withdrawal/avoidance. There are no differences
in graft survival between patients treated with or with-
out maintenance corticosteroids beyond the first week
after kidney transplantation and avoidance beyond the
first week after kidney transplantation reduces adverse ef-
fects. Early withdrawal and avoidance studies show in-
creased acute rejection rates but without an effect on graft
survival [136, 137, 229]. In contrast, steroid withdrawal
studies later than one month after transplantation gener-
ally show increased rejection rates. Long-term follow up is
required to fully assess these effects. It is clear that close
vigilance is required with steroid avoidance regimes since
acute rejection rates will probably be higher. Patients with
graft rejection should probably be maintained on long-
term oral steroids [88].
Higher doses of CNIs are required during the first 3
months when the recipient’s immune response is receiv-
ing the most allostimulation. There is theoretically a
good reason to reduce the immunosuppressive load after
this time to reduce the incidence of drug-related adverse
effects (i.e. reduce CNI target levels). Analysis of RCTs
has shown that CNI withdrawal leads to higher rejection
rates without any improvement in graft survival. Com-
parison of lower dose CNI regimes with higher doses
have generally shown little difference in outcomes [107]
but in some cases better renal function has been
attained. Those seeking a fuller discussion of these stud-
ies are referred to the 2009 KDIGO guidelines [104].
While there is some evidence that m-TORis can allow
reduced doses of CNIs and better graft function at 1
year after transplantation, these agents are poorly toler-
ated and are associated with higher rejection rates [222].
Two studies have investigated the substitution of m-
TORis for CNIs between 1 and 6 months after trans-
plantation. While both studies demonstrated short-
term improvements in renal function, there were no
significant improvements in long term graft or patient
outcomes [26, 27, 224]. A systemic review demon-
strated a significant reduction in the rate of malignancy
with sirolimus but a 43% increase in overall mortality
rate compared to controls [108]. The exact role of m-
TORis in the early stages after transplantation is uncer-
tain but at this time they should only be used as second
line agents.
Belatacept is a fusion protein that blocks costimulatory
pathways involved in T cell activation, which has to be ad-
ministered by regular intravenous infusions. It has been
used in KTRs as an alternative to ciclosporin and signifi-
cant improvement in renal function and better graft hist-
ology at 1 year has been demonstrated [215]. More recent
studies have confirmed improved graft function, which
was sustained at 5 years, but also an association with the
development of PTLD [177]. A meta-analysis concluded
that belatacept has no demonstrable effect on rejection
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rates, patient or graft survival [135]. However, it was asso-
ciated with significantly better graft function and hist-
ology. It is currently a valuable second line agent that may
be particularly useful in certain clinical situations (e.g.
poor adherence, haemolytic uraemic syndrome). In 2011,
the US Food and drug administration issued a warning
over risks of PTLD and progressive multifocal
leukoencephalopathy (PML) with belatacept [152].
Guideline 3.13 – KTR: monitoring of immunosuppression
We suggest that long-term monitoring of immunosup-
pression levels is required as follows:
 Tacrolimus and ciclosporin levels should be
monitored. The frequency should be 3 times a week
immediately after the transplant. Levels should
checked when any medication with possible
interactions is prescribed or when there is
unexplained graft dysfunction (2C)
 Tacrolimus should be monitored by the C0 trough
level, while ciclosporin can be monitored by either
trough (C0) or 2-h post dose (C2) level (2C)
 Tacrolimus and ciclosporin levels should be
available within 24 h of taking blood samples (2C)
 The utility of monitoring mycophenolic acid (MPA)
C0 levels is uncertain (2D)
 Sirolimus should be monitored by the C0 trough
level (2C)
Rationale Therapeutic drug monitoring is advisable for
drugs with a narrow therapeutic index. For tacrolimus
and ciclosporin the absorption may vary in the early
stages after transplantation but usually stabilises within a
month. Both drugs may exhibit both inter-patient and
intra-patient variability. Tacrolimus and ciclosporin are
traditionally monitored by 12-h C0 trough levels, but in
the case of ciclosporin there is some evidence that C2
levels may also be used although target ranges are less
well established and the logistics of sample collection
are more complex. There is little evidence directly com-
paring different target levels of the same drug in a con-
trolled fashion. Drug monitoring of MMF is best carried
out by measuring the area under the curve (AUC) but
clinical studies have not been conclusive [107, 114, 213].
C0 levels correlate poorly with AUC and remain un-
proven and rarely used in clinical practice. Sirolimus
levels should be monitored since toxic effects correlate
with high drug levels and C0 levels correlate well with
AUC [98, 111].
Guideline 3.14 – KTR: prescribing and the use of generic
agents
We suggest that generic immunosuppression com-
pounds should not be used unless they have been shown
to be bioequivalent and approved by the European
Agency for the Evaluation of Medicinal Products (2D)
Guideline 3.15 – KTR: prescribing and the use of generic
agents
We suggest that KTRs should be made aware of the ex-
istence of generics and the dangers of indiscriminate
usage (2D)
Guideline 3.16 – KTR: prescribing and the use of generic
agents
We suggest that drugs should be prescribed by brand
name where unproven generic substitutes are available
(2D)
Guideline 3.17 – KTR: prescribing and the use of generic agents
We suggest that KTRs should be followed closely after
switching to a generic preparation until a new steady
state is established (2D)
Audit Measure
 The use of generic agents should be monitored and
audited
Rationale The introduction of many generic prepara-
tions of tacrolimus, ciclosporin and MPA has occurred
in the last 5 years. These offer potential cost savings but
with the risk that these medications are not truly bio-
equivalent due to the limitations of the regulatory
process. This has led to differences in both pharmacoki-
netic and clinical terms, compared with the original
agents.
Immunosuppressive drugs in common use have nar-
row therapeutic windows, with significant risk of
under- and over-immunosuppression and, with CNIs,
the risk of nephrotoxicity due to over-exposure.
Plasma CNI levels are carefully measured in practice,
with narrow therapeutic ranges. Assessment of generic
agents requires only that time-averaged plasma con-
centrations (area-under-the-curve) fall between 80 and
125% of the original preparation in normal subjects.
Differences in bioavailability due to food, or other fac-
tors, are not assessed. For ciclosporin the bioavailabil-
ity of generic agents extends across this range and is
influenced by food, thus switching between generic
agents may result in major differences in drug expos-
ure. This may be minimised by careful measure of drug
exposure after switching between agents and generic
preparations (“named” generics). When the choice of
generic is left to the dispenser this is likely to result in
variable exposure. The same issues may apply to tacro-
limus but the bioavailability of this agent is less vari-
able, and to other generic immunosuppressants such
as MPA, although monitoring of this agent is not
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usually undertaken in clinical practice. For these rea-
sons a local protocol for the use of generic agents
should be available to all involved in the care of trans-
plant recipients, specifically those who write and dis-
pense prescriptions.
Kidney Transplant Recipient (KTR): acute rejection
(Guidelines 4.1-4.12)
Guideline 4.1 – KTR: diagnosis of acute rejection
We recommend that a transplant renal biopsy should be
carried out before treating an acute rejection episode un-
less this will substantially delay treatment or pose a sig-
nificant risk to the patient (1C)
Guideline 4.2 – KTR: diagnosis of acute rejection
We suggest that two cores of renal tissue should be
obtained if possible since this will increase the sensitivity
of the investigation (2C)
Guideline 4.3 – KTR: diagnosis of acute rejection
We recommend that a 16 gauge automated core biopsy
needle is used where possible to provide the best
compromise between diagnostic usefulness and patient
tolerance of the procedure (1C)
Guideline 4.4 – KTR: diagnosis of acute rejection
We recommend that a protocol transplant renal biopsy,
defined as a biopsy performed in a stable graft without
clinical evidence of acute rejection (proteinuria, rising
creatinine), be considered in the setting of persisting de-
layed graft function (DGF) (1C)
Guideline 4.5 – KTR: diagnosis of acute rejection
We recommend that routine C4d and SV40 staining
should be performed upon transplant biopsies (2C)
Guideline 4.6 – KTR: diagnosis of acute rejection
We suggest that a serum sample be sent at the time of
renal biopsy (for graft dysfunction) to look for HLA-
specific antibodies (2C)
Audit measures
 Severity of biopsy proven acute rejection (BPAR)
recorded by Banff criteria
 The percentage of KTRs with BPAR in first
3 months and the first 12 months
 The percentage of KTRs requiring TDAs to treat
rejection within the first year
 Complication rates after renal transplant biopsy
 The percentage of KTRs with a donor-specific HLA
antibody at the time of biopsy
Rationale Historically, unresolved acute rejection epi-
sodes invariably led to graft loss so it is rational to
treat such episodes unless the treatment is likely to do
more harm than good. Rejection episodes are charac-
teristically associated with loss of graft function but
diagnosis is best established by a percutaneous biopsy
since it differentiates rejection clearly from other
causes of graft dysfunction. Recognition of different
forms of rejection may inform different treatment regi-
mens (e.g. antibody mediated rejection).
Two cores of tissue should be obtained as this ap-
proach establishes the diagnosis of acute rejection with
a sensitivity of 99% versus 91% when only one core is
obtained [39]. The use of a 16 gauge automated core
biopsy needle yields higher numbers of glomeruli and
thus increased diagnostic usefulness without an in-
crease in complication rate compared with an 18 gauge
needle [149, 161].
Biopsy is performed when there is acute graft dysfunc-
tion with the aim of providing a histological diagnosis to
confirm clinical suspicion. However, renal scarring may
be too advanced for any intervention to lead to
significant improvement. Subclinical acute rejection
[185] is defined as histological rejection in the absence
of clinical evidence of altered graft function diagnosed
on protocol biopsies and logically one might expect that
early detection would lead to improved outcomes. In
most patients, with modern immunosuppression re-
gimes, there is little evidence that treatment of SCAR
improves outcomes and a clear link between SCAR and
chronic rejection has not yet been proven [180]. There
are multiple reasons for this: there is no large multi-
centre prospective study; the induction, baseline and
maintenance immunosuppression regimes vary in stud-
ies; some protocol biopsies are actually indication biop-
sies and thus cannot show SCAR; and the Banff criteria
was designed for diagnostic biopsies and not for protocol
biopsies where the findings may not fit with the criteria
[71]. There is randomised control trial evidence that
there is no benefit from protocol biopsies performed
within the first 6 months of transplantation in low risk
patients on a standard immunosuppressive regimen
[180]. There are two clinical settings where protocol bi-
opsy is of value. In delayed graft function (DGF) there is
increased risk of graft failure; ‘silent’ acute rejection may
account for a significant proportion of this increased risk
[167]. In a more specialised setting, in very high and
high immunological risk patients, if SCAR is detected
this should be treated as it may improve outcome [112,
204]. The optimal timing and frequency of protocol bi-
opsy is not clear but we suggest that it be considered in
the clinical settings outlined above at days 7–10 for
DGF. In high-risk transplants, protocol biopsy will typic-
ally be at 3 months.
It is recommended to stain all biopsies for C4d and to
send a serum sample for detection of human leukocyte
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antigen (HLA) specific antibodies to facilitate diagnosis of
acute antibody mediated rejection in line with joint BSHI/
BTS guidelines and those of The Transplantation Society
[22, 204]. The Banff criteria were revised in 2013 to
acknowledge the occurrence of antibody mediated
rejection in the absence of detectable C4d staining [71].
Immunohistopathologic evidence of recent interaction of
antibody with the vascular endothelium is necessary for
the diagnosis and this may include, but is not limited, to
C4d positivity. Conversely, diffuse C4d staining may occur
in the absence of morphological evidence of active rejec-
tion or graft dysfunction, primarily in ABO incompatible
transplantation.
An episode of acute rejection is a period of uncer-
tainty and is likely to cause anxiety in KTR and/or
their carers. Good communication explaining the
treatment rationale and likely outcomes of rejection is
important in addressing these concerns.
Guideline 4.7 – KTR: treatment of acute rejection
We suggest that borderline acute cellular rejection should
be treated in the context of acute graft dysfunction (2D)
Guideline 4.8 – KTR: treatment of acute rejection
We recommend that high dose intravenous corticoste-
roids should be the first line treatment for acute cellular
rejection (1D)
Guideline 4.9 – KTR: treatment of acute rejection
We suggest that maintenance steroids should be added
or restarted in steroid-free patients undergoing acute re-
jection of any type (2D)
Guideline 4.10 – KTR: treatment of acute rejection
We suggest that lymphocyte depleting agents may be
considered for refractory acute cellular rejection or ag-
gressive vascular cellular rejection (i.e. Banff category 4
Type II and III) (2C)
Guideline 4.11.1 – KTR: treatment of acute rejection
We suggest that antibody mediated rejection (AMR)
should be treated with one or more of the following mo-
dalities: steroids; plasma exchange; intravenous immuno-
globulin; anti-CD20 antibody; lymphocyte-depleting
antibody or bortezomib (2C)
Guideline 4.11.2 - KTR: treatment of acute rejection
We recommend that the BTS guidelines on antibody in-
compatible transplantation for management of rejection
in the context of antibody incompatible transplantation
(1A-D)
Guideline 4.12 – KTR: treatment of acute rejection
We suggest after an episode of rejection (unless associ-
ated with low CNI levels) that azathioprine should be
switched to MPA-based immunosuppression, MPA
should be started or the existing dose of MPA maxi-
mised and ciclosporin and sirolimus should be switched
to tacrolimus (2D)
Rationale The management of antibody incompatible
transplantation is reviewed extensively in the recent BTS
guidelines on this topic [24]. In contrast to SCAR, bor-
derline acute cellular rejection detected in the context of
graft dysfunction should be treated in the knowledge
that if untreated, the infiltrates may progress into rejec-
tion with consequent deterioration in transplant func-
tion [138, 231]. However, there is little evidence to guide
therapy, treatment is controversial, and there is evidence
that borderline infiltrates will not automatically progress
into rejection [10, 231].
The majority of acute cellular rejection episodes re-
spond to treatment with corticosteroids [66, 192]. The op-
timal regime for steroid administration has not been
determined but intravenous methylprednisolone on three
consecutive days is commonly used [66]. If intravenous
steroid is precluded, high dose oral steroid can be utilised.
The use of T cell depleting antibodies (TDAs) in milder
grades of cellular rejection (Banff category 4 type I) may
be more effective in restoring renal function but results in
significantly greater side effects [196, 223]. If renal func-
tion does not return to baseline with steroid and/or ATG,
or if there is a new decline in function after successful
treatment of an acute rejection episode, a repeat biopsy
should be considered to rule out additional rejection or
other causes of graft dysfunction (e.g. concurrent acute
tubular necrosis or BK nephropathy). Treating more se-
vere cellular rejection (Banff category 4 Type IIa, IIb or
III) and steroid unresponsive episodes with TDAs often
improves graft function although a thorough risk-benefit
assessment of such treatment should be undertaken [196,
223]. There is some evidence that adding an MPA product
after such episodes or substituting azathioprine with MPA
will result in fewer subsequent rejection episodes [145].
Intensifying immunosuppression after a rejection episode
may help prevent further rejection including the following:
maximising the dose of MPA product and switching
ciclosporin or sirolimus to tacrolimus [33, 144, 202, 203].
If AMR is diagnosed, there is limited evidence that
treatment with alternative modalities including plasma-
pheresis, immunoadsorption, intravenous immunoglobu-
lin or monoclonal antibodies may be beneficial [176].
Trial evidence is conflicting and of low quality. Small
non-randomised studies and case reports suggest that
monoclonal antibodies targeting B cell function and thus
antibody production (rituximab and bortezomib) may be
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of benefit, as may terminal complement inhibition with
eculizimab. However, there is insufficient evidence to
recommend these agents and the risks and benefits, par-
ticularly of biologic therapies, must be considered on an
individual basis [117, 123, 176].
Kidney Transplant Recipient (KTR): Chronic Allograft
Injury (CAI) Guidelines 5.1-5.)
Guideline 5.1 – KTR: Diagnosis of Chronic Allograft Injury
(CAI)
We recommend that early identification of graft injury is
desirable to maximise the potential to intervene. A pro-
active and systematic approach should be employed to
manage graft dysfunction (1C)
Guideline 5.2 – KTR: Detection of Chronic Allograft Injury
(CAI)
We suggest that renal function should be monitored
at each clinic visit by assessment of serum creatinine
and qualitative evaluation of urine protein excretion
by dipstick supplemented by spot PCR or ACR if
positive (2C)
Guideline 5.3 – KTR: Diagnosis of Chronic Allograft Injury
(CAI)
We suggest that renal biopsy is the optimal investigation
for parenchymal causes of graft dysfunction where the
cause is uncertain (2C)
Guideline 5.4 – KTR: Diagnosis of Chronic Allograft Injury
(CAI)
We suggest that renal biopsies in patients with chronic-
ally deteriorating function should routinely be stained
for C4d and SV40 (2C)
Guideline 5.5 – KTR: Diagnosis of Chronic Allograft Injury
(CAI)
We suggest that a serum sample should be sent at the
time of renal biopsy (for graft dysfunction) to look for
HLA-specific antibodies (2C)
Audit Measures
 Severity of CAI recorded by BANFF criteria
 The percentage of KTRs with positive C4d staining
on biopsy
 The percentage of KTRs with a donor specific HLA
antibody at the time of biopsy
Rationale Unfortunately there are currently no good
markers of early allograft injury. A number of non-
invasive biomarkers have been proposed including urine
and serum microRNA profiling but the clinical utility and
additive predictive value of these compared to traditional
markers – serum creatinine, proteinuria, histopathology –
is uncertain [5, 6, 76, 84, 132]. Graft damage can be
detected by protocol biopsy but the utility of this approach
is unproven. Studies show that all protocol biopsies at
3 years post transplantation display evidence of some
degree of CAI and by 5 years this is classed as moderate
or severe in over 60% of patients [147]. Therefore current
best practice consists of vigilant monitoring of simple clin-
ical markers of allograft function including serum creatin-
ine and proteinuria [4, 68]. More complex and expensive
approaches such as monitoring serum anti-HLA anti-
bodies also remain unproven.
Deterioration in graft function is a heterogeneous
entity with multiple causes, both immunological and
non-immunological [56, 186]. Treatment may entail dia-
metrically opposite strategies and therefore deterioration
of allograft function should be investigated by percutan-
eous biopsy if possible. Tissue samples should be exam-
ined by an experienced renal histopathologist and
classified according to the Banff criteria [71]. Staining
for C4d deposition and SV40 antigen should be routinely
available because positive staining will affect the treat-
ment strategy.
Although there is not yet any proven therapy, it is
important to recognise chronic humoral rejection diag-
nosed according to the Banff criteria [71, 142, 196]. The
detection of anti-HLA antibodies and C4d staining on
transplant biopsy are associated with worse clinical out-
comes [16, 60, 81, 102, 115, 133, 186, 226]. More re-
cently the complement binding ability of anti-HLA
antibodies has been shown to impact upon graft survival
[124]. Post-transplant screening for anti-HLA antibodies
has been suggested but there is not yet a solid evidence
base to recommend it routinely in low or moderate im-
munological risk patients, nor to routinely determine the
complement fixing ability of detected anti-HLA anti-
bodies. In patients who are sensitised or deemed high
immunological risk, a timetable of post-transplant anti-
body sampling should be agreed within the transplant
centre. This is in line with the recommendations set out
in both the BSHI/BTS and the Transplantation Society
Guidelines [22, 204].
Identifying a process likely to lead to a decline in long
term transplant function will be worrying for patients/
their carers. It is important to involve patients in treat-
ment decisions including need for biopsy, alterations to
the immunosuppressive regime. This may also include
plans for return to dialysis or re-transplantation.
Guideline 5.6 – KTR: treatment of chronic allograft injury
We suggest that chronic allograft injury should be
treated:
 By withdrawal of calcineurin inhibitors (CNIs) if
there is either histological evidence of CNI toxicity
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or non-specific interstitial fibrosis and tubular atro-
phy (2C)
 By intensification of immunosuppression if there is
evidence of ongoing immune injury (cellular
rejection and/or humoral rejection) (2C)
In a similar fashion to other patients with CKD follow-
ing similar preventative strategies and with timely refer-
ral to low clearance services (2D)
Rationale There is some evidence that withdrawal of
CNIs following chronic deterioration of graft function is
beneficial [50, 158, 224]. The role of m-TOR-inhibitors as
replacements for CNIs is uncertain but this approach
should be avoided in patients with eGFR <40 mL/min/
1.73 m2 and/or significant proteinuria (PCR >50 or ACR
>35 mg/mmol) [185]. An overview of treatment options
dictated by findings on allograft biopsy is shown in Table 2.
There is no proven therapy for chronic humoral rejec-
tion and studies are ongoing in this area. Whilst to date
there is limited high quality (e.g. randomised controlled
trials) evidence to support this strategy, it seems logical
to consider increased immunosuppression in the face of
ongoing immunological damage to the kidney transplant.
Employing measures used in other non-transplant
patients with CKD is likely to be of benefit; for example,
some studies show that anaemia is more prevalent in
transplant patients and is associated with poor outcomes
[227]. The BTS ‘Management of the Failing Kidney
Transplant’ guideline covers this aspect of management
in detail [23].
Guideline 5.7 – KTR: renal biopsy in chronic allograft injury
We suggest that a renal transplant biopsy is indicated:
 If there is a persistent unexplained elevation of
creatinine or failure to return to baseline after an
episode of biopsy proven acute rejection (BPAR)
(1C)
 Every 7–10 days during delayed graft function
(DGF) (2C)
 If expected renal function is not achieved within 4–8
weeks (2D)
 If sustained new onset proteinuria develops (PCR
>50 mg/mmol or ACR >35 mg/mmol) (2C)
Audit Measures
 The percentage of KTRs with positive C4d staining
on biopsy
 The percentage of KTRs with a donor specific HLA
antibody at the time of biopsy
Rationale Unexplained changes in serum creatinine are
an important clinical marker of rejection and proteinuria
is associated with poor outcome; both should be investi-
gated for a treatable cause [5, 32, 72].
Kidney Transplant Recipient (KTR): cardiovascular disease
and lifestyle (Guidelines 6.1-6.6)
Guideline 6.1– KTR: hypertension
We suggest that the management of hypertension take
into account that:
 Blood pressure should be recorded at each clinic
visit (1C)
 Clinic blood pressure should be <140/90 mmHg in
clinic (130/80 mmHg if PCR >50 or ACR >35) (2C)
 Home blood pressure recordings and 24-h ambulatory
recordings may be helpful in some instances but lower
BP targets should then be set (home and or ambula-
tory daytime measures <135/80 mmHg) (2D)
 There is no evidence that any antihypertensive agent
is better than any other and effort should be focused
on achieving absolute levels rather than the use of
individual agents (2D)
 Inhibitors of the renin-angiotensin system may be
more effective in the minimisation of proteinuria but
they should be used with caution in the first
3 months post transplant (2C)
 Resistant hypertension may be due to transplant
renal artery stenosis and should be investigated
according to local practice (2D)
Audit Measures
 The proportion of patients receiving a target blood
pressure of 140/90 mmHg or 130/80 mmHg in the
presence of proteinuria PCR > 100 or ACR > 70)
 Proportion of patients with proteinuria assessed by
dipstick and, if present, quantified at each clinic visit
Rationale The goal of treatment of hypertension in KTR
is to reduce the risk of the cardiovascular complications
of hypertension (stroke, heart failure, myocardial infarc-
tion and arrhythmia) and to preserve or minimise the
rate of long term decline in graft function. Blood pres-
sure targets and strategies for treatment should be tai-
lored to the individual patient taking into account
proteinuria, the presence of end organ damage such as
left ventricular hypertrophy, potential side effect profile
of antihypertensive therapy, immunosuppression, and
any other relevant lifestyle factors such as safety in preg-
nancy in female KTRs of childbearing age.
Hypertension is common following kidney trans-
plantation and is associated with reduced graft and pa-
tient survival. Many patients require treatment with
more than one antihypertensive agent and despite
therapy many patients fail to meet treatment targets.
Hypertension is a side effect of immunosuppressive
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therapy, in particular corticosteroids and calcineurin
inhibitors, and may also be a consequence of poor
graft function leading to salt and water retention.
Defining the target optimal target blood pressure in
KTRs is challenging and is mainly based on observa-
tions made from retrospective registry studies. When
office/clinic blood pressure is felt to be unrepresenta-
tive of actually blood pressure (such as suspected
‘white coat’ hypertension, resistant hypertension), home
recordings or ambulatory monitoring can be useful, but
most studies demonstrate lower measures with these
methods and revised targets should be set [218]. Resist-
ant hypertension, often defined in the general popula-
tion as clinic BP >160/90 mmHg on 3 or more
antihypertensive agents is common in KTR and sug-
gests that further work up is required to exclude trans-
plant renal artery stensosis, non-compliance, or rarer
causes of secondary hypertension e.g. primary aldoster-
onism or phaeochromocytoma. In the general popula-
tion, there has been a move towards more frequent use
of ambulatory blood pressure monitoring or home
blood pressure measurements for the diagnosis and
treatment of hypertension. This is a reasonable strategy
for KTRs with the proviso that KTRs are known to be
at higher risk of the complications of hypertension and
there should be a low threshold for therapeutic
intervention when blood pressure targets are exceeded.
Where resistant hypertension is suspected, target end
organ damage should be assessed using echocardiog-
raphy to look for the presence of left ventricular
hypertrophy.
There are no large scale trials of any single antihy-
pertensive agent in KTRs. Treatment strategies are
therefore either defined from extrapolation from other
populations or from retrospective analysis of registry
data or post hoc studies from clinical trials. The use of
blockers of the renin-angiotensin system has been as-
sociated with improved patient and graft survival in
some but not all retrospective studies, and effectively
reduces proteinuria in KTRs although recent trial data
suggest that this may not translate into better longer
term graft outcomes [109, 154, 209]. However, this
may be balanced against the risk of hyperkalaemia,
more anaemia, and the drop of GFR when these agents
are started. The drop in GFR may be predictable and if
non progressive and <30% may reflect simply the
haemodynamic effect of starting these agents rather
than any more serious consequence of these agents. A
greater drop in GFR is suggestive of transplant renal
artery stenosis and may prompt further imaging. The
use of dihydropyridine calcium antagonists may also
have benefits in hypertension associated with use of
Table 2 Interpretation of the Banff Classification
Banff code Descriptive term Pathophysiology Interpretation Treatment
i Interstitial
inflammation
Infiltration of interstitium by
mononuclear cells
Linked with cellular rejection
but also viral infection
Intensification of immunosuppression
–often pulsed intravenous steroids
t Tubulitis Infiltration of renal tubules by
mononuclear cells
Linked with cellular rejection
but also viral infection
Intensification of immunosuppression
–often pulsed intravenous steroids
g Glomerulitis Margination of inflammatory
leukocytes in the glomerular
capillary loops
Marker of humeral rejection Intensification of immunosuppression if
not too much chronic damage
v Arterial
inflammation
Inflammation of arterial wall
with infiltration of mononuclear
cells
Marker of either severe cellular
rejection or humeral rejection
Intensification of immunosuppression if
not too much chronic damage
ptc Peritubular
capillaritis
Margination of inflammatory
cells in the peritubular capillaries
Marker of humeral rejection Intensification of immunosuppression if
not too much chronic damage
ci Interstitial Fibrosis Interstitial structure replaced
by fibrosis
Marker of chronic damage Poor prognostic sign – may prompt
reduction in CNI
ct Tubular atrophy Interstitial tubules involuted Marker of chronic damage Poor prognostic sign – may prompt
reduction in CNI
cg Transplant
glomerulopathy
Interposition of mesangium
and thickening of GBM
Associated with proteinuria
and development of DSAs
– End lesion of CAMR
Poor prognosis – no known treatment
but intensification of immunosuppression
often practiced
mm Mesangial
matrix expansion
Increase of thickness of
mesangial matrix
Marker of microvascular damage
to glomerulus
Usually interpreted in association with
other findings
cv Arterial
fibrointimal
thickening
Expansion of intima between
endothelium and media
Marker of chronic damage
– non-specific
Poor prognostic sign – vascular protective
measures
ah Arteriolar
hyalinosis
Nodular deposition of hyaline CNI toxicity but non-specific
(e.g. HT, DM, lipids)
Reduction or withdrawal of CNI
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CNIs. Modification of immunosuppression including
switching from ciclosporin to tacrolimus, minimisa-
tion of calcineurin inhibitors, switching to CNI-free
immunosuppression and withdrawal of corticosteroids
may all be associated with lower blood pressure. All
these strategies may be considered in the presence of
resistant hypertension in the absence of any other
cause, when graft function is stable and there have
been no recent rejection episodes.
Guideline 6.2 – KTR: dyslipidaemia
We suggest that the management of dyslipidaemia take
into account that:
 Fasting lipid levels should be measured on an annual
basis in all renal transplant recipients (2C)
 Treatment targets should be the same as in the
general population (2C)
 KTRs at increased primary or secondary CV risk
receive statin therapy to reduce the risk of coronary
artery disease (2C)
 The choice and dose of statin should take into
account concurrent immunosuppression. High dose
simvastatin (≥40 mg daily) should be avoided in
conjunction with ciclosporin and/calcium channel
antagonists (2D)
Audit Measures
 Proportion of renal transplant patients with measure
of lipids
 Proportion of renal transplant patients taking statins
for primary and secondary prevention of
cardiovascular disease
 Proportion of transplant patients receiving other
lipid lowering treatments
 Proportion of patients achieving dyslipidaemia
targets
Rationale Patients with CKD who have reached end
stage renal disease (ESRD) requiring transplantation
are at high cardiovascular risk. The leading cause of
graft loss is death with a functioning graft, whilst the
leading cause of death in renal transplant recipients is
cardiovascular disease. Therefore, it is imperative that
cardiovascular risk is lowered aggressively to optimise
patient and graft outcomes. Kidney transplant recipi-
ents have a high prevalence of dyslipidaemia, includ-
ing raised total, HDL and LDL cholesterol and
hypertriglyceridaemia [94]. Dyslipidaemia is a conse-
quence of immunosuppressive therapy, specifically
corticosteroids, ciclosporin (more so than tacrolimus),
sirolimus and everolimus [141]. Lipid lowering therapy
is likely to beneficial for many renal transplant
recipients. Unlike previous versions of these guide-
lines, we have taken account of the recent JBS3 guide-
lines, which suggest measurement of non-fasting lipid
profile [14]. It seems sensible to use similar clinical
practice for assessment of lipid status in KTR as in the
general population. However, the JBS3 calculator is
not likely to be appropriate for use in KTR and other
calculators specific to KTR exist [197]. In keeping with
the ethos of lifetime risk rather than an absolute LDL-
cholesterol value being used as a trigger for interven-
tion with lipid lowering therapy, we suggest that a 10%
7-year risk of a major adverse cardiac event using the
risk calculator derived from the ALERT study, or a
10% 10-year risk of myocardial infarction or stroke
using the JBS3 calculator (which is likely to underesti-
mate risk in transplant patients) should be used as a
trigger for consideration of lipid lowering therapy.
Performing a baseline assessment of lipid status
allows concordance with therapy to be assessed and
additionally allows estimation of the level of lipid
reduction. Concordance with therapy is recognised to
be challenging in renal transplant recipients who are
usually on multiple agents often including immuno-
suppression, antihypertensive therapy and antimicro-
bial prophylaxis. Lipid assessment should be
performed once immunosuppressive drug dosing is
stable and the risk of acute rejection requiring cortico-
steroid therapy has fallen. This is likely to be least 3
months after transplantation although this will vary
with individual patients. Specific targets for treatment
have not been recommended as they are difficult to
define and are not well defined in the general popula-
tion. The choice and dose of statin is more likely to be
selected on the basis of safety and the immunosup-
pressive regimen rather than potency in lowering LDL
cholesterol.
Statins have similar effects on the secondary dyslipidae-
mia seen in renal transplant recipients as is demonstrated
in primary dyslipidaemia in the general population. The
ALERT study showed in a large scale randomised
controlled trial that long-term treatment with fluvastatin
(40–80 mg per day) compared with placebo non-
significantly reduced the risk of coronary death or non-
fatal MI in ciclosporin-treated renal transplant recipients
[86, 87]. In this study, fluvastatin led to a significant 35%
relative reduction in the risk of cardiac death or non-fatal
MI. 18.7% patients in ALERT were diabetic at baseline
and diabetes was a risk factor for cardiac death in this
study [93]. However, there was not a significant reduction
in cardiac events in diabetic renal transplant patients.
Statins are metabolised by the cytochrome P450 micro-
somal enzyme system and concurrent therapy with inhibi-
tors of this system such as ciclosporin or tacrolimus can
lead to greater statin exposure and higher risk of side
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effects such as rhabdomylosis. This risk appears to be
greater with simvastatin and is lowest with fluvastatin or
pravastatin [174, 201]. Ezetimibe appears to be safe in
renal transplant recipients; although it has been reported
to interfere with ciclosporin levels, recent reports suggest
this is unlikely to be a major clinical problem [25, 208].
Fibrates have a high risk of side effects and are best
avoided in renal transplant recipients.
Guideline 6.3 – KTR: diabetes mellitus
We suggest that the detection and treatment of diabetes
mellitus in KTR should include the following:
 Screening for the development of post transplant
diabetes mellitus (PTDM) by dipstick urinalysis and
measurement of blood sugar level at each clinic visit
(2C)
 Post transplant immunosuppression should take into
account risk factors for the development of diabetes.
(2C)
 We recommend that diagnosis of PTDM is made
based onWHO criteria for diagnosis of diabetes
mellitus based on fasting or random blood, serum
HBA1c or oral glucose tolerance testing (1C)
 We suggest that a diagnosis of PTDM is made once
patients are established on stable maintenance
immunosuppression (2D)
 We suggest that post-transplant diabetes should be
managed in collaboration with specialists in diabetic
medicine (2D)
 All units should have a protocol for the
management of post-transplant diabetes (2C)
 KTR with diabetes (either prior to transplantation or
PTDM) should undergo screening for diabetic
complications (retinal screening, foot care,
neuropathy) in line with guidelines for non KTR
patients with diabetes (2D)
Audit Measures
 Incidence of post transplant diabetes mellitus
(PTDM) at 3 months and at annual intervals
thereafter
 Proportion of patients who require insulin, and in
whom remedial action is undertaken – minimisation
of steroids and switching of CNIs
 The proportion of patients with PTDM enrolled in
screening for extra-renal complications of PTDM
Rationale Post-transplant diabetes mellitus (PTDM) is
common following successful kidney transplantation and
occurs in 5–20% of KTRs. PTDM impacts on patient
survival, particularly by increasing the risk of cardiovas-
cular disease. Data are limited on the exact magnitude of
increase in cardiovascular risk associated with PTDM or
the risk of microvascular complications of PTDM (in-
cluding retinopathy, neuropathy and late graft failure
due graft diabetic nephropathy). Risk factors for PTDM
are well established and include increasing age, obesity,
known glucose intolerance or metabolic syndrome,
hepatitis C and family history. Transplant-specific risk
factors for PTDM include tacrolimus use (compared to
ciclosporin) and corticosteroids. Whilst a number of
studies and prior guidelines have advocated switching
immunosuppression specifically to minimise the risk of
PTDM, this should be balanced against the need for
optimal graft function and risk of acute rejection and
subsequent need for further steroids, which may para-
doxically increase PTDM risk. Similarly, steroid mini-
misation is an attractive strategy for reducing the risk of
PTDM, but published evidence does not consistently
support this.
Many patients will exhibit transient hyperglycaemia in
the first month after transplantation due to a combin-
ation of high dose corticosteroids and CNI inhibition.
Whilst this identifies a group of patients at risk of
PTDM, it is not useful to over diagnose PTDM and it is
reasonable to confirm the presence of PTDM once im-
munosuppression is stable, typically at 3 months post
transplantation.
Once diagnosed, care of the KTR with PTDM should
be co-ordinated in a similar fashion to patients with dia-
betes without transplants. Particular focus should be
paid to maintenance of good glycaemic control, treat-
ment of conventional cardiovascular risk factors and
screening for the microvascular complications of PTDM.
There is no current evidence for any particular
hypoglycaemic in KTRs and lifestyle measures, oral
hypoglycaemic agents and insulin can all be used to ad-
dress glycaemic control.
Guideline 6.4 – KTR: ischaemic heart disease
 We suggest that KTRs receive standard treatment
for ischaemic heart disease including thrombolysis,
revascularisation, and secondary prevention (2C)
Audit Measures
 Proportion of patients with ischaemic heart disease
 Proportion of patients suffering myocardial
infarction
 Proportion of patients undergoing primary
revascularisation
 Proportion of patients receiving secondary
prevention with a statin, anti-platelet agents and
RAS blockers
Rationale Coronary artery disease (CAD) is common in
patients with ESRD, including transplant recipients, and
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is a major contributory factor to cardiovascular mortality
and morbidity. The presence of coronary artery disease
often influences the decision to transplant list patients
with ESRD. Irrespective of the presence or severity of
pre-transplant CAD, once transplanted, CAD is reported
in 14–20% (previous myocardial infarction MI or CAD)
[29, 38, 164]. Post transplantation myocardial infarction
(MI) is common, affecting approximately 11.1% of pa-
tients by 3 years post transplantation, and much of this
risk is experienced early, within the first 6 months of
transplantation [118]. MI risk has been shown to be
linked with modifiable factors including delayed graft
function, post transplantation diabetes and graft fail-
ure, and in turn, MI predicts graft failure and death.
Additionally, the ALERT trial [86] demonstrated that
determinants of non-fatal myocardial infarction in
RTR include total cholesterol level, prior CAD and
previous acute rejection. Combined, these data suggest
that whilst RTR share common risk factors with the
general population for CAD and MI post transplant-
ation, there are further graft-specific aspects to post-
transplant CAD. It is known that patients with ESRD,
including transplant recipients, are less likely to
undergo cardiac intervention (bypass grafting, throm-
bolytics or per-catheter therapies), possibly because of
higher complication rates, and are less likely to receive
secondary prevention. There is no reason to believe
that transplant recipients will benefit less than pa-
tients in the general population, many of whom have
renal impairment. Patients with renal transplants
should have equal access to cardiac investigations and
surgery as patients without CKD.
Guideline 6.5 - KTR: smoking cessation
We recommend that smoking should be discouraged in
transplant recipients (1A)
Audit Measures
 Proportion of KTRs who smoke
 Proportion of cigarette smoking KTRs who have
been given formal advice or offer help with cessation
Rationale Cigarette smoking is strongly associated with
the reduced life expectancy, several forms of malignancy,
respiratory disease and premature cardiovascular disease
in the general population. Whilst the evidence is less
comprehensive in KTRs, cigarette smoking has been
shown to be associated with reduced patient survival,
malignancy, and increased cardiovascular events [119,
164]. In the general population, various intervention
strategies have been shown to be beneficial in encour-
aging smoking cessation (nicotine replacements - gum,
patch, and inhaled, counselling, and Bupropion) [44, 92].
Maintenance of abstinence is challenging, as 10–20% of
former smokers will resume smoking following previ-
ously successful cessation [52]. The long-term benefits
of smoking cessation have not been proven in transplant
recipients, nor are long-term studies likely to be per-
formed. However, strategies for smoking cessation are
safe and likely to produce the same benefits seen in
other populations or public health studies. A local strat-
egy should be available and record made of the advice
given and available.
Guideline 6.6 KTR: lifestyle measures
We suggest that advice on healthy lifestyle forms a rou-
tine part of post-transplant care:
 Maintenance of a healthy diet should be encouraged
(2C)
 An ideal weight should be targeted (body mass
index (BMI) ≤25 kg/m2) (2C)
 Weight management services should be available
(2C)
 We suggest that KTRs participate in physical activity
at a level similar to that recommended to age and
co-morbidity matched counterparts from the general
population (2D)
 Alcohol consumption should be within national
guidelines (2D)
 Recreational drug use should be avoided (2D)
 The use of over-the-counter medications (without
discussion with clinical staff ) and non-proprietary
medications (e.g. herbal medicines) should be dis-
couraged (2D)
Audit Measures
 Proportion of patients who are obese
Rationale Transplant recipients have often been sub-
jected to dietary restriction associated with advanced
CKD, removal of which after transplantation is one of
the factors contributing to weight gain, the metabolic
syndrome, diabetes and their sequelae. Whilst metabolic
syndrome and obesity have been associated with poorer
graft outcomes, the overall impact on obesity on patient
and graft outcomes is less than might be expected [150].
However, as longer follow up data emerge from the gen-
eral population regarding the association between obes-
ity and cardiovascular disease and malignancy [12] it
would seem prudent for KTRs to avoid obesity. KTR
should have access to dietary advice, and to weight man-
agement services if necessary. Pharmacological interven-
tion for obesity has not been assessed in a clinical trial
in KTR and may interfere with the metabolism and ab-
sorption of immunosuppressive agents [58]. Bariatric
surgery is similarly unproven in this population and
likely to have a higher incidence of side effects and
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potential interactions. Dose reduction or withdrawal of
corticosteroids helps weight loss but more intensive
monitoring is essential around the time of dose changes.
There are very limited data on any specific dietary in-
terventions in KTRs. However, as premature cardiovas-
cular disease is a leading cause of death following
transplantation, we suggest that patients follow a diet,
which minimises intake of saturated fat, sugar and salt.
We suggest that in addition to body weight control,
dietary advice should be given to ensure adequate cal-
cium and magnesium intake and control of serum phos-
phate level.
We suggest that KTRs avoid dietary intake of produce
associated with an increased risk of infections such as
listeria monocytogenes, campylobacter jejuni, etc., e.g.
raw shellfish, unpasteurised dairy products. Grapefruit
juice should be avoided due to the potential for interfer-
ence in the metabolism of immunosuppressant drugs
(tacrolimus, ciclosporin) by intestinal CYP34A, leading
to increased drug levels.
KTRs have often been restricted in their ability to keep
physically active whilst on dialysis. Maintaining a
‘healthy’ level of physical activity is likely to be beneficial
and excise based interventions have been shown to have
a positive impact on quality of life and aerobic capacity
in KTRs [79]. Participation in sporting events is often
beneficial. Due to the position or the transplant, partici-
pation in sports where a direct blow to the allograft is
possible is not recommended (e.g. kickboxing).
Alcohol abuse occurs in a small proportion of KTRs
though the prevalence and severity of alcohol misuse is
difficult to define. Alcohol use within recommended
guidelines after transplantation is likely to be safe, whilst
alcohol or substance abuse are associated with an in-
creased of premature death [127, 157]. Access to coun-
selling, addiction services and rehabilitation should be
available.
Non-steroidal anti-inflammatory drugs are widely
available ‘over the counter’ and should be avoided. There
are potential interactions with OTC and “herbal medica-
tions” (e.g. St. John’s Wort). Patients should be aware of
the increased risk and potential sequelae of drug interac-
tions, and encouraged to discuss any proposed changes
to medication with clinical staff or an expert renal
pharmacist.
Kidney Transplant Recipient (KTR): neoplasia
(Guidelines 7.1-7.3)
General concepts
Neoplasia is more common in KTRs due to impaired
immunosurveillance. In particular, virally driven cancers
are more prevalent e.g. human papilloma (HPV)-induced
cervical cancer (see Table 3). The relative risk of cancer
is higher in younger patients (20x relative risk of
neoplasia) than older patients (2x for over 65 s) [127,
157]. KTRs with neoplasia have worse outcomes than
members of the general population, probably due to in-
creased toxicity from treatment. Preventative strategies
are therefore paramount, which may involve screening
and the minimisation or modification of immunosuppres-
sive therapy. If cancer develops then part of the treatment
will involve reducing and/or modifying immunosuppres-
sive therapy. This is likely to be more beneficial in those
cancers with higher relative risks in KTRs (e.g. more likely
to have a clinical impact in non-melanoma skin cancer
than pancreatic cancer). Emerging evidence supports the
notion that low dose immunosuppression and the use of
m-TORi may reduce the incidence and recurrence of
some cancers [31, 148, 228].
Guideline 7.1 – KTR: screening for cancer
We suggest that the organisation of screening for neo-
plasia in KTRs take into account:
Table 3 Association of risk of common malignancies in KTRs
Relative risk KTR Common cancers
High RR >5 Kaposi’s sarcoma
Eye
Lymphoma
Kidney
Non-melanoma skin
Lip
Thyroid
Medium RR 1-5 Melanoma
Cervix
Vulvovaginal
Bladder
Colon
Lung
Stomach
Oesophagus
Oropharynx and Larynx
Myeloma
Anus
Leukaemia
Hepatobiliary
No increase Breast
Prostate
Ovary
Uterus
Pancreas
Brain
Testis
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 Screening should be similar to the general
population for cervical, breast, colon and prostate
cancer (2C)
 Screening is not recommended for renal cell
carcinoma (2C)
 Patient education pre and post transplantation (1C)
 Patients should be aware of malignancy risk and
encouraged to report symptoms which may
represent de novo malignancy (e.g. breast or
testicular lumps) (2D)
 Skin surveillance by a healthcare professional at least
biannually up to 5 years post-transplant and annu-
ally from 5 years post-transplant (2C)
 Patients with cirrhosis should undergo an annual
hepatic ultrasound and determination of serum
alpha feto-protein (2C)
Audit Measure
 Proportion of patients having screening procedures
for neoplasia at the annual review clinic
Rationale The merits of any screening programme must
balance the individual’s risk of developing the disease,
their prognosis if detected, and the risk of harm from
screening. Screening should be individualised and reflect
co-morbidities and other competing risks (e.g. vascular
disease). Some authors have advocated more frequent
screening (e.g. annual cervical screening) but there is lit-
tle evidence to support these assertions. Thus screening
should follow the pattern in the general population for
most common cancer [159]. The national cancer screen-
ing protocols are described on the NHS Cancer Screen-
ing Programme (NHSCSP) website [148]. Patient
education regarding neoplasia should be undertaken
pre-transplant, with reinforcement post-transplant.
Education should include breast, testicular and skin self-
examination. Information about risk factors for the
development of NSMC should also be included [74].
That all KTRs should undergo skin surveillance is not in
doubt but the frequency of survey to optimally balance
early detection and treatment with finite resource is un-
clear [64]. The incidence of non-melanoma skin cancers
increases with duration post-transplant and skin surveil-
lance should therefore be more frequent [74, 170]. En-
couragement of self-examination and education should be
reinforced in the initial years following transplant, supple-
mented with skin surveillance by a trained healthcare pro-
fessional at least biannually [200]. From 5 years post-
transplant, skin surveillance should be undertaken annu-
ally to reflect the increased likelihood of developing
NSMC [170] Smoking cessation should be encouraged
in all KTRs. A formal protocol for the management of
smoking cessation should be available in each
transplant centre (see Guideline 6.5 – KTR: smoking
cessation)
Guideline 7.2 – KTR: Non-Melanoma Skin Cancer (NMSC)
We recommend that KTRs should be educated about
the adverse effects of solar exposure (1C)
Guideline 7.3 – KTR: Non-Melanoma Skin Cancer (NMSC)
We suggest that KTRs that an individualised assessment
of hazard should be made according to risk factors (2C)
Guideline 7.4 – KTR: Non-Melanoma Skin Cancer (NMSC)
We recommend that patients should be encouraged to
cover their skin in direct sunlight and to use total sun-
block (Sun Protection Factor ≥ 50) (1D)
Guideline 7.5 – KTR: Non-Melanoma Skin Cancer (NMSC)
We suggest that self-examination should be encouraged
with guidance provided. This should be supplemented
by at least biannual review by a trained healthcare pro-
fessional up to 5 years post-transplant and annual review
from 5 years (2C)
Guideline 7.6 – KTR: Non-Melanoma Skin Cancer (NMSC)
We suggest that the prescription of acitretin as chemo-
prophylaxis be considered in those with ≥2 previous
NMSC if there are no contraindications (2B)
Rationale Certain patient groups are at higher risk of
non-melanoma skin cancer, particularly the fair-skinned
living in a sunny climate. Other risk factors include occu-
pation, behaviour, previous skin cancer, childhood solar
exposure and family history. It is sensible to minimise ex-
posure and use sun block. Acitretin (0.2–0.4 mg/kg/day)
may reduce total NSMCs in those who have had ≥2 previ-
ous NSMCs and thus use should be considered in those
with previous skin cancer [97]. There is some evidence
that sirolimus reduces the incidence of second tumours
but at the expense of increased side effects and possibly
adverse effects on graft function [101, 183, 199]. Recent
studies suggest that m-TORi may be associated with fewer
NMSC, particularly cutaneous Kaposi sarcoma and recent
data suggest that switching KTRs to sirolimus is associ-
ated with reduction of secondary NMSC [57, 183]. The
role of HPV vaccination in KTRs is unclear, but it is an
inactivated vaccine that can be administered safely either
before or after transplantation [111].
Guideline 7.7 – KTR: immunosuppression in cancers
We suggest that the overall level of immunosuppression
should be reduced if neoplasia develops (2C)
Baker et al. BMC Nephrology  (2017) 18:174 Page 27 of 41
Guideline 7.8 – KTR: immunosuppression in cancers
We suggest that m-TORis are considered as alternative
immunosuppressive agents in KTRs who develop de
novo maligancy (2C)
Guideline 7.9 – KTR: immunosuppression in Kaposi’s
sarcoma
We suggest that m-TORis has specific anti-tumour
effects in Kaposi’s sarcoma and switching to this medica-
tion should be considered (2C)
Rationale There is no evidence that any particular
immunosuppressant agent is linked to a particular cancer
other than the association of TDAs and PTLD [106, 148].
It is generally agreed that the level of immunosuppression
should be decreased when cancer occurs. This decision
should be individualised according to the stage of the
cancer at diagnosis, the likely impact of a reduction in
immunosuppression, the availability of treatment for the
tumour, and potential drug interactions between the
chemotherapy and immunosuppressive agents. In general,
the effect of reducing the overall level of immunosuppres-
sion is more likely to be beneficial where the relative risk
of the tumour in KTRs is higher. m-TORis are indicated
in the treatment of Kaposi sarcoma in addition to reduced
levels of overall immunosuppression [200].
Kidney Transplant Recipient (KTR): infection
complications (Guidelines 8.1–8.7)
Guideline 8.1 – KTR: vaccination
Guideline 8.1.1 – KTR: vaccination
We recommend that KTRs:
 Should be vaccinated with inactivated viruses as per
the normal population (1D)
 Should receive annual influenza vaccination unless
contraindicated (1C)
Guideline 8.1.2 – KTR: vaccination
We suggest that KTRs:
 Should have HBsAb levels rechecked annually and
consider revaccination if antibody titres fall below
10mIU/ml (2D)
 Should not receive live attenuated vaccines (2C)
 Should receive pneumococcal vaccine and a booster
every 5 years (2D)
Rationale Vaccination for KTRs and their household
members should ideally be completed prior to transplant-
ation. A minimum of 4 weeks is recommended between
vaccination with live attenuated vaccines and transplant-
ation. After transplantation, there is no evidence to link
vaccination with rejection. After transplantation it is safe
to administer inactivated vaccines but live attenuated
vaccines should be avoided (see Table 4 below) as small
studies have demonstrated concerns regarding their safety
and efficacy in KTRs. Vaccination should probably be
carried out at least 3 months and preferably 6 months
after transplantation when the immunosuppression has
been reduced. Consideration should be given to vaccin-
ation of close household contacts where appropriate e.g.
Varicella vaccination for children of VZV seronegative
KTRs.
The HPV vaccine has been assessed in a small study of
transplant recipients. Although the vaccine was safe and
tolerated, immunogenicity was suboptimal [113]. There
is a strong link between HPV and anogenital and non-
melanoma skin cancer and, given the tolerability of these
vaccines, some authors have recommended vaccination
for all female KTRs aged between 9 and 26 [35]. Malaria
prophylaxis should consist of chloroquine in sensitive
areas, but it may increase levels of ciclosporin. Prophy-
laxis should therefore start 2 weeks prior to departure to
permit monitoring of drug levels. In areas of
chloroquine-resistance three options can be used: atova-
quone and proguanil; mefloquine; or doxycycline. The
choice of agent will be dictated by local preference and
side effect profile but drugs should be started a few
weeks prior to departure to allow for checks of renal
and hepatic function, full blood count and immunosup-
pression levels. More extensive guidance is available for
KTRs who are travelling overseas [77].
Guideline 8.2 – KTR: cytomegalovirus disease
Guideline 8.2.1 – KTR: prophylaxis and treatment of CMV
disease
We recommend:
Table 4 Commonly used inactive and live attenuated vaccines
Inactive Vaccine Live Attenuated Vaccine
Inactivated Influenza Varicella Zoster
Hepatitis A Mumps
Hepatitis B Rubella
Inactivated Polio Measles
Diptheria BCG
Tetanus Smallpox
Meningococcal Yellow Fever
Pneumococcal Oral Salmonella
Human Papilloma Virus Oral Polio
Rabies
Anthrax
Intramuscular Salmonella
Japanese encephalitis
Inactivated intravenous cholera vaccine
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 Prophylaxis should be continued for 3–6 months,
until immunosuppression has been reduced to long-
term maintenance level (1B)
 Treatment should be administered for 6 weeks after
treatment with a TDA (1C)
Guideline 8.2.2 – KTR: prophylaxis and treatment of CMV
disease
We suggest:
 All transplant units should have the ability to
measure CMV serological status and the detection
and quantification of viral load (2D)
 Donor and recipient CMV sero-positivity should be
recorded at the time of transplantation (2D)
 A written protocolised strategy based either on
prophylaxis, or pre-emptive therapy, or both should
be implemented (2D)
 For the treatment of mild and moderate CMV
disease, oral valganciclovir and intravenous
ganciclovir are of equivalent efficacy (2C)
 Treatment of life-threatening CMV disease should
be initiated with intravenous ganciclovir (2D)
 Treatment duration should be determined by
monitoring viral load (2C)
Audit Measure
 Incidence of CMV disease.
Rationale CMV infection is the most common serious
viral infection affecting renal transplant recipients [89,
110]. It occurs most commonly in CMV naïve recipients
of a kidney from a CMV positive donor. However, sero-
positive transplant recipients may be affected by reacti-
vation of CMV infection and by primary infection with a
new genotype. CMV infection is associated with more
intensive immunosuppression, treatment of acute rejec-
tion episodes and the use of TDAs. For CMV disease
there is clear evidence that prophylaxis reduces the se-
verity, delays the onset and prevents CMV infection in
CMV negative recipients of CMV positive kidneys [85,
125]. CMV infection is also associated with concomitant
infection by other herpes viruses, the significance of
which is uncertain but prevention of which may be an
added benefit of prophylaxis over pre-emptive strategies
[90]. CMV prophylaxis is therefore recommended in
CMV negative KTRs from a CMV positive donor (D
+/R-), and for seropositive KTRs (D-/R+ or D+/R+) ex-
posed to more intensive immunosuppression, in particu-
lar TDAs.
In CMV negative recipients of a CMV positive kidney
the use of oral antiviral therapy – specifically valaciclovir,
aciclovir, ganciclovir, or valganciclovir – is proven to
delay the onset of CMV disease, to prevent CMV disease
in a proportion of patients, and to limit the severity of
disease. It is important to recognise that a proportion of
patients will develop CMV disease after stopping
prophylaxis and will require clinical and virological
monitoring for at least 3 months following the stopping
of prophylactic therapy [90]. At present, evidence exists
for the use of valaciclovir and valganciclovir [91, 212]. In
clinical practice, valaciclovir is not widely available or
used, and valganciclovir is the agent of choice. The dose
of valganciclovir should be adjusted according to renal
transplant function. Most commonly, and based on the
available evidence, antiviral prophylaxis is usually contin-
ued for 90–180 days following transplantation (depending
on D and R status). The rationale is that reduction of im-
munosuppressive therapy over this period will allow the
immune system to combat viral replication once prophy-
lactic therapy is withdrawn [9, 126].
Treatment of CMV disease is equally effective with
either oral valganciclovir or intravenous ganciclovir
[77, 89]. However, this study excluded patients with
life-threatening CMV infection and it is probably ad-
visable to initiate treatment with intravenous therapy
in such circumstances [110].
Guideline 8.3 – KTR: Epstein Barr virus infection
Guideline 8.3.1 – KTR: EBV infection
We recommend that immunosuppression should be
reduced or stopped following the development of PTLD
(1C)
Guideline 8.3.2 – KTR: EBV infection
We suggest:
 Both donor and recipient should have their EBV
serology recorded at the time of transplantation (2D)
 All high risk (D+/R-) patients (including adults)
should have EBV viral load measured immediately
after transplantation, monthly for 6 months, and 3
monthly to 1 year (2C)
 EBV viral load should be monitored after the
treatment of rejection (2C)
 Total immunosuppression should be reduced when
EBV titres rise significantly (2C)
Audit Measures
 Rates of EBV infection and PTLD amongst KTRs
 Completeness of records for EBV donor and
recipient serology
Rationale After transplantation, primary EBV infection
may present with a broad spectrum of disorders ranging
from asymptomatic infection to high grade non-Hodgkin
lymphoma (PTLD). EBV seronegative KTRs, undergoing
seroconversion post transplant, are up to 50 times more
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likely to develop PTLD compared to their seropositive
counterparts. The EBV genome is found in more than 90%
of PTLD occurring during the first year after transplant-
ation [3]. Vigilance is therefore essential, especially since
EBV viraemia usually precedes the development of PTLD
by 4–16 weeks [178]. However, assays for EBV viral load
can often be positive in asymptomatic patients (false posi-
tives) and so clinical correlation and attention to changes
in viral load are essential. Risk factors for early PTLD in-
clude primary EBV infection, young donor age, CMV infec-
tion, and induction with TDAs. The use of antiviral agents
(e.g. valaciclovir or valganciclovir) or immunoglobulins in
response to rising viral loads is unproven and cannot be
recommended. Since the immune response to EBV in-
fected tissue is thought to depend on EBV-specific T cell
responses it is logical to reduce immunosuppressive treat-
ment in the face of clinical EBV infections and PTLD.
Guideline 8.4 – KTR: Varicella Zoster Virus infection
Guideline 8.4.1 – KTR: VZV infection
We recommend:
 Primary infection (chickenpox) should be treated
with intravenous aciclovir or oral valaciclovir until
the lesions scab over (1C)
 Uncomplicated shingles should be treated with oral
acyclovir or valaciclovir until the lesions scab over
(1D)
 Disseminated (>2 dermatomes), ocular or invasive
shingles should be treated with intravenous aciclovir
until the lesions scab over, together with a reduction
in immunosuppression (1B)
 Varicella-susceptible KTRs (i.e. VZV IgG negative)
with primary exposure to VZV should receive
intravenous immunoglobulins, ideally within 96 h,
but up to a maximum of 10 days following exposure.
If unavailable or after 10 days, oral aciclovir should
be administered for seven days (1D)
Guideline 8.4.2 – KTR: VZV infection
We suggest:
 Patients on the waiting list who are VZV IgG
seronegative should be vaccinated prior to
transplantation (2D)
 Immunosuppression should be reduced during
primary infection (2D)
Audit Measures
 Annual rates of primary VZV and shingles infection
 Completeness of records for VZV recipient serology
in KTRs
Rationale Acquired by 90% of the population before
adulthood, primary infection with VZV causes chicken-
pox. Thereafter the virus remains latent in the cranial
nerve and dorsal root ganglia. Secondary reactivation
results in shingles and typical dermatomal blistering skin
lesions. Primary infection can be acquired by direct skin
contact and by airborne droplet transmission [78, 160].
Primary disease in KTRs can be devastating with severe
skin lesions, widespread visceral involvement and dis-
seminated intravascular coagulation. In immune naïve
and immunosuppressed individuals, treatment with
pooled varicella zoster immunoglobulin has been shown
to prevent or ameliorate VZV infection. It seems sens-
ible to vaccinate VZV naïve patients on the waiting list
since the vaccine has been shown to be safe [160]. As a
live attenuated vaccine, VZV vaccine should not be ad-
ministered post transplant.
Guideline 8.5 – KTR: Herpes Simplex Virus infection
Guideline 8.5.1 – KTR: HSV infection
We recommend:
 Superficial HSV (1 or 2) infection should be treated
with appropriate oral agents until the lesions have
resolved (1D)
 Systemic HSV infections should be treated with
intravenous aciclovir and a reduction in
immunosuppression until a response occurs and oral
medication continued for at least 14 days (1C)
Guideline 8.5.2 – KTR: HSV infection
We suggest that KTRs suffering frequent recurrent HSV
infection should consider oral prophylaxis (2D)
Audit Measure
 Rates and outcomes of HSV infections
Rationale There is an increased potential for superficial
HSV infections to become disseminated or invasive in
KTRs. Reactivation most commonly occurs in the first few
weeks after transplantation and complicated disease can
become life threatening involving multiple organs includ-
ing the liver, lung and central nervous system. Since treat-
ment is safe and effective, it seems sensible to treat early
infections [172]. Due to their gravity, complicated infec-
tions should be treated with intravenous therapy and
reduction in immunosuppression.
Guideline 8.6 – KTR: BK nephropathy
Guideline 8.6.1 – KTR: BK nephropathy
We recommend that confirmed BK nephropathy should
be treated by reduction in immunosuppression (1D)
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Guideline 8.6.2 – KTR: BK nephropathy
We suggest:
 Screening should also be carried out when renal
function deteriorates in an unexplained fashion (2D)
 KTRs should be screened for BKV viral load or by
performing urine microscopy for decoy cells or by
PCR on urine or serum (2C)
 Suspected BK nephropathy should be confirmed by
renal biopsy, which should be stained for SV40. Two
cores containing medullary tissue should ideally be
examined (2D)
 Immunosuppression should be reduced when the
serum BKV load exceeds 104 copies/ml (2C)
 There is no established specific treatment for BK
nephropathy (2D)
 Re-transplantation can safely be considered in
patients who have BK nephropathy diagnosed in an
earlier graft (2C)
Audit Measures
 Rates of BK viral infection in screening tests
 Rates and outcomes of BK nephropathy
Rationale The human polyoma BK virus is linked to
two major clinical syndromes in KTRs, namely BK
nephropathy (BKN) and transplant ureteric stenosis
[15, 43, 169]. BKN occurs in up to 10% of KTRs and is
responsible for a significant number (15–50%) of allo-
graft losses. 90% of young adults have serological
evidence of prior infection and the DNA virus remains
latent in the uroepithelium. The virus becomes active
and replicates under the influence of immunosuppres-
sion. BK virus is cytolytic and so epithelial cells are
shed in the urine as decoy cells and free virus can be
detected in the urine. With increased viral replication,
BKV spills into the blood and can be detected as BK
viraemia by PCR. Approximately half of patients with
high level viruria (>107 copies/mL) will develop signifi-
cant BK viraemia (104 copies/mL) and half of these will
develop histological BKN. Risk factors for BKV include
not only both donor and recipient characteristics but
also high immunosuppressive burden and intensifica-
tion of immunosuppression. Definitive diagnosis re-
quires demonstration of the virus in renal tissue,
usually by staining with the antibody for large T anti-
gen of SV40. Since the infection can be focal and pref-
erentially affects the renal medulla, two cores
including medulla should be examined [48, 83]. The
mainstay of treatment is reduction of immunosuppres-
sion but there is no evidence that reducing any par-
ticular immunosuppressive agent is particularly
beneficial [75, 82]. Common approaches include stop-
ping anti-proliferative agents or reducing CNI levels in
the face of rising viral replication [95]. Specific agents
such as intravenous immunoglobulin, quinolones,
cidofovir and leflunomide have been shown to have
anti-viral activity but there is no definitive evidence to
show that they offer any advantage over simply redu-
cing the total immunosuppressive burden [130, 155,
171]. Prospective trials are urgently required to explore
this question. If a first graft is lost due to BKN there is
no evidence that this will adversely affect the outcome
of subsequent grafts and no special precautions are ne-
cessary (e.g. allograft nephrectomy) prior to re-listing
[46].
Guideline 8.7 – KTR: pneumocystis jirovecii infection-
treatment and prophylaxis
We suggest:
 All patients with confirmation (microscopy or PCR)
of Pneumocystis jirovecii in respiratory secretions
should be treated for 14 to 21 days with co-
trimoxazole orally or intravenously (15–20 mg/kg in
three or four divided doses) (2B)
 Patients with contraindications to treatment with co-
trimoxazole should receive pentamidine (4 mg/kg/day
intravenously) (2B)
 Adjunctive glucocorticoid therapy may be
considered in patients with severe disease (2D)
 All patients should receive 3–6 months of treatment
with co-trimoxazole 480 mg daily for Pneumocystis
jirovecii prophylaxis following renal transplantation
(1B)
Rationale Diagnosis of Pneumocystis pneumonia (PCP)
requires confirmation by microscopy or PCR from
respiratory secretions (induced sputum after inhaled
saline or bronchoalveolar lavage). In non-HIV infected in-
dividuals, co-trimoxazole has been shown to be effective.
Co-trimoxazole has excellent bioavailability and enteral
administration is preferred, although intravenous therapy
may be necessary in acutely unwell patients. In patients
with contraindications to co-trimoxazole, intravenous or
aerosolised pentamidine is a suitable alternative although
it is associated with a higher rate of side effects. Alterna-
tive agents against pneumocystis jirovecii include dapsone
or atovaquone. The duration of therapy should be be-
tween 14 and 21 days. The use of additional glucocortic-
oid therapy is not associated with improved survival in
non-HIV patients, although treatment with prednisolone
has been associated with quicker recovery from severe
PCP infection in one small observational study [156]. As a
result, PCP prophylaxis with co-trimoxazole is recom-
mended and has shown to be beneficial in meta-analysis
of 12 randomised studies in 1245 immunocompromised
individuals [67].
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Guideline 8.8 – KTR: post-transplant infection prophylaxis
 All patients should receive 3–6 months of treatment
with co-trimoxazole 480 mg daily (1B)
 Oral antifungal prophylaxis should be administered
for 1 week month after transplantation (2C)
 In selected patients, prophylaxis against
mycobacterium tuberculosis with daily isoniazid
(supplemented with pyridoxine) should be instituted
for 6 months after transplantation (2C)
Rationale In addition to benefit for PCP, there is good
evidence that co-trimoxazole provides effective prophy-
laxis against urinary tract infections after renal transplant-
ation [42, 63]. Alternatives include cephalosporins and
fluoroquinolones. Alternative agents against pneumocystis
jirovecii include dapsone, atovaquone or aerosolized
pentamidine.
Candida infection is common after renal transplantation
and can cause considerable morbidity. It is usually ac-
quired from colonisation of the oral mucosa and so topical
oral preparations offer a simple form of prevention with-
out the potential toxicity of systemic preparations.
Tuberculosis in KTRs is usually due to reactivation of
quiescent disease under the influence of immunosuppres-
sion. In other immunosuppressed populations treatment
of latent tuberculosis prevents progression to clinically
active tuberculosis. A recent Cochrane Database review
recommended prophylaxis with isoniazid (for up to
1 year) in selected recipients at high risk of tuberculosis
(based on prior infection or exposure, or patients whose
country of origin has a high incidence of tuberculosis
infection) with careful monitoring of liver function, es-
pecially in patients who are hepatitis B and C positive
[2, 42].
Guideline 8.9 – KTR: Hepatitis E Virus
We recommend that Hepatitis E Virus (HEV)-screened
blood components should be given to all KTR (1C)
Rationale There has been an increase in the number of
reports of cases of hepatitis E virus (HEV) in the United
Kingdom. The infection is usually mild and self- limit-
ing in the immunocompetent but there is increasing
evidence that HEV infection in patients receiving im-
munosuppression may lead to persistent infection,
which may lead to chronic hepatitis and cirrhosis. HEV
may be transmitted through the use of blood and blood
products, through transplantation and through diet
(especially inadequately cooked pork and pork products
such as sausages and offal). Liver tests may be normal
or show mild hepatitis. The favoured diagnostic test is
by HEV polymerase chain reaction. Liver biopsy may
show histology. Conventional management of HEV
infection is review immunosuppression and reduce or
minimise immunosuppressive burden where possible. If
there is no serological evidence e clearance within 3
months, consider a 3-months course of Ribavarin (note
this use is off licence) [181, 182].
Kidney Transplant Recipient (KTR): bone and joint disease
(Guidelines 9.1-8.7)
Guideline 9.1 KTR: osteoporosis
We suggest:
 KTRs suffering from osteoporosis or at high
potential risk should be considered for steroid-
avoiding immunosuppression (2D)
 KTRs on longterm steroids or at high risk for
osteoporosis should undergo DEXA scanning if
eGFR >30 ml/min/1.73 m2 (2D)
 treatment should be according the RCP guidelines
for steroid-induced osteoporosis (2D)
Audit Measures
 Prevalence of KTRs on corticosteroids
 Frequency of bisphosponate usage amongst KTRs
 Incidence of fractures amongst KTRs
Rationale All KTRs have a complex bone disorder
whereby the effects of immunosuppression are superim-
posed on an underlying Chronic Kidney Disease Mineral
and Bone Disorder (CKD-MBD). Any guidance should
be used in conjunction with existing guidelines for
CKD-MBD [104]. The risk of fractures after renal trans-
plantation is high but there is no accurate way to predict
fracture risk. Clinical tools have not been validated in
KTRs. Bone Mineral Density may not reflect the future
risk of fracture in KTRs, particularly in those with eGFR
<30 mL/min/1.73 m2 [201]. In addition bisphosphonates
are contraindicated in subjects with eGFR <30 mL/min/
1.73 m2. There is evidence that treatment with calcium
and vitamin D derivatives attenuates post-transplant bone
loss and maintains bone mineral density without excess
hypercalcaemia [96, 175, 207]. Corticosteroids seem to be
the principal determinant of bone turnover and bone vol-
ume so it seems logical to target interventions towards re-
duction or withdrawal of these drugs [175]. There are
numerous guidelines for corticosteroid induced osteopor-
osis including those of the Royal College of Physicians and
it seems reasonable to follow them [40, 175]. Newer
agents such as denosumab, a monoclonal antibody, which
inhibits RANK ligand, seem to be safe in renal impairment
with the caveat that serum calcium needs to be closely
monitored, as the risk of hypocalcaemia is increased [13].
One randomised control trial of denosumab in the KTR
showed some benefit on preservation of bone mineral
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density, but at the expense of greater numbers of urinary
tract infection [17].
Guideline 9.2 KTR: tertiary hyperparathyroidism
We suggest:
 Severe hyperparathyroidism should be treated prior
to transplantation (2D)
 Cinacalcet can be used in KTRs (2C)
 We suggest treatment should be the same as for
other patients with CKD (2D)
Audit Measures
 Incidence of hyperparathyroidism
 Incidence of parathyroidectomy
 Usage of cinacalcet
Rationale Post-transplant hyperparathyroidism is a
complex entity that may represent a true high bone
turnover state but also low bone turnover [18]. Dietary
intake of phosphate, longstanding phosphate retention
whilst on dialysis treatment, followed by sometimes pro-
found urinary phosphate losses in the early post trans-
plant period all contribute to the complexity of
managing this condition. In the latter case the suppres-
sion of parathyroid hormone (PTH) secretion may lead
to adynamic bone disease and the only certain way to
distinguish between the two types of mineral and bone
disorder (MBD-CKD) is by bone biopsy. There are
contradictory data on the effect of parathyroidectomy
post transplantation but it seems sensible to treat se-
vere hyperparathyroidism prior to transplantation [59,
100]. In KTRs, cinacalcet may be used; it successfully
corrects hypercalcaemia and elevated PTH level,
seems to improve bone mineral density, and may also
have an antihypertensive effect [11, 198, 233]. Caution
should be exercised with high doses [187]. In hyper-
parathyroidism refractory to pharmacological agents,
parathyroidectomy also provides a benefit but should
only be pursued when potential risks of such a proced-
ure are considered.
Guideline 9.3 gout
Guideline 9.3.1 treatment of gout
We recommend that neither allopurinol nor febuxostat
should not be administered with azathioprine (1B)
Guideline 9.3.2 –KTR: treatment of gout
We suggest:
 Hyperuricaemia should be treated when associated
with gout, tophi or uric acid stones (2D)
 Non steroidal anti-inflammatory drugs (NSAIDs)
should be avoided in KTRs (2D)
 Episodes of gout may be treated with brief courses
of oral prednisolone (2D)
 Colchicine is an effective treatment for gout in
KTRs (2D)
Audit Measure
 Frequency of gout and hyperuricaemia amongst
KTRs
Rationale Gout is common after transplantation and may
cause significant morbidity. Hyperuricaemia increases the
risk of gout and may also be linked with increased rates of
cardiovascular disease [1]. In CKD, febuoxstat may have
superior urate lowering effects compared with allopurinol
[188]. This observation is also borne out in the transplant
population where febuxostat appears to effectively lower
urate levels without adversely affecting renal transplant
function, although long term outcome data are lacking
[195, 205]. Important drug interactions alter the strategy
for managing gout in KTRs. In particular, use of concomi-
tant use of such agents with azathioprine can precipitate
potentially fatal blood dyscrasias. CNIs are associated with
higher uric acid levels and may contribute to the develop-
ment of gout.
Guideline 9.4 –KTR: calcineurin inhibitor bone pain
We suggest:
 Reducing or withdrawing CNIs should be
considered in KTRs with intractable bone pain (2D)
 Dihydropyridine calcium antagonists also may be
beneficial (2D)
Rationale It has become increasingly recognised that
CNIs may cause bone pain, which preferentially affects
bones in the lower legs [37, 69]. Bone marrow oedema
can be demonstrated on magnetic resonance imaging
(MRI) scanning and treatment involves reducing CNI
levels and the use of dihydropyridine calcium antago-
nists [55].
Kidney Transplant Recipient (KTR): haematological
complications (Guidelines 10.1–10.3)
Guideline 10.1 –KTR: anaemia
We suggest that chronic anaemia should be managed in
the same way as other patient with CKD (2D)
Audit Measure
 Prevalence of anaemia amongst KTRs
Rationale Anaemia is common in the KTR population,
with reports suggesting a prevalence of 20–30% of KTRs,
and may be associated with poor outcomes [73, 227]. Its
aetiology is multifactorial and may include relative
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erythropoietin deficiency related to suboptimal graft
function, haematinic deficiency, post-transplant infec-
tion, and adjunctive antimicrobial therapy (valganci-
clovir, co-trimoxazole). It may be exacerbated by
immunosuppressant therapy, especially antiprolifera-
tive agents, and these may be tapered or stopped to
improve haemoglobin levels. Management should be
similar to other patients with CKD [49]. There is one
small randomized controlled trial suggesting benefit
with haemoglobin correction using an erythropoeisis-
stimulating agent [34]. However, this is in contrast to
larger similar studies in the non-transplant CKD
patients where haemoglobin correction to similar
levels was associated with adverse outcomes such as
increased stroke risk [162].
Guideline 10.2 – KTR: − polycythaemia
We recommend that initial treatment should be with
angiotensin converting enzyme inhibitors (ACEIs) or
with angiotensin receptor blockers (ARBs) (1C)
Guideline 10.3 – KTR: − polycythaemia
We suggest:
 Haemoglobin levels should be monitored at every
clinic visit (2D)
 Treatment should be initiated if the haematocrit or
packed cell volume exceeds 52% in men and 49% in
women (2D)
 Venesection may be used in refractory cases (2D)
Audit Measure
 Prevalence of post transplant erythrocytosis amongst
KTRs
Rationale Post-transplant polycythaemia (erythrocytosis)
is common after renal transplantation and may be associ-
ated with significant morbidity and mortality [103, 217].
The overall effect on long term outcome is less clear,
although it is likely that it increases risk of thrombotic
events [232]. Studies have shown that ACEIs and ARBs
are associated with a drop in haematocrit in KTRs [69].
Kidney Transplant Recipient (KTR): reproductive issues
(Guidelines 11.1-11.5)
Guideline 11.1 – KTR: conception and contraception
(female)
We recommend that MPA-containing immunosuppres-
sant drugs should be stopped prior to conception and
replaced appropriately (1A)
Guideline 11.2 – KTR: conception and contraception
(female)
We suggest:
 KTRs should wait for 1 year after transplant and
have stable function before attempting conception
(2C)
 Counselling regarding fertility and reproduction
should be offered to female KTRs and their partners
either prior to transplantation or soon afterwards
(2D)
 m-TORi should be stopped prior to conception and
replaced as appropriate (2D)
 Pregnancy should be managed jointly with an
Obstetrics department with experience of care of
KTRs (2D)
 We suggest that KTRs receive aspirin 75 mg daily to
reduce the risk of pre-eclampsia from 12 weeks ges-
tation until birth of the baby unless there are contra-
indications (2C)
 The risks and benefits of breastfeeding should be
discussed (2D)
 Contraception advice should be similar to the
general population (2D)
Guideline 11.3 – KTR: conception and contraception (male)
We recommend:
 Male KTRs are advised that MPA containing
compounds have theoretical teratogenic potential in
men taking these agents (1D)
 KTRs should be advised that m-TORi reduce the
male sperm count and counselled accordingly (1C)
Guideline 11.4 – KTR: conception and contraception (male)
We suggest:
 All immunosuppressive drugs other than m-TORi
can be used in male KTRs. Advice for MPA is as
Guideline 11.3 (2D)
 The decision to continue MPA containing
compounds in a male KTR wishing to conceive
should balance a the risk of theoretical
teratogenicity against the risk of rejection on
changing from MPA to azathioprine (2D)
 Men on m-TORi who wish to conceive should dis-
continue these agents prior to conception and re-
place them as appropriate (2D)
 Men who wish to maintain fertility should avoid m-
TORi or bank sperm prior to starting these drugs (2D)
Audit Measure
 Pregnancy rates and outcomes should be monitored
Rationale Female fertility returns rapidly after successful
renal transplantation and KTRs and their partners need to
be counselled about potential pregnancy [139]. Pregnancies
in KTRs should be deemed above average risk with
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increased rates of maternal hypertension, pre-eclampsia,
prematurity, low birth weight and caesarean section [19,
41]. The risk of pregnancy to allograft function is probably
small, particularly with good baseline function [19]. Im-
munosuppressive drugs can all have effects on the foetus
and appropriate caution should be exercised. Sirolimus and
MPA compounds are teratogenic and should be avoided in
females [7, 41]. Recent advice from the MHRA also advises
that MPA compounds should be avoided in male KTRs
prior to conception as there is a theoretical risk of terato-
genicity associated with males fathering children whilst
receiving these drugs [194]. This advice does not appear to
be confirmed in registry studies detailing outcomes in
pregnancies fathered by KTRs [194]. Therefore, in men,
any theoretical risk of foetal abnormality associated with
use of MPA compounds, should be balanced against the
risk of rejection or decline in graft function associated with
changing immunosuppression. Further information on this
issue has been generated by the Renal Association’s Preg-
nancy and Chronic Kidney Disease Rare Disease Group
and is available on the website RareRenal.org: http://bit.ly/
Mycophenolate_recs.
Alternative immunosuppression should therefore be
considered prior to conception. All immunosuppressants
are excreted in breast milk, albeit in tiny quantities, and
are usually contraindicated. However, toxicity has not
been reported after breastfeeding with ciclosporin, pred-
nisolone, azathioprine and tacrolimus [101, 232]. Aspirin
is now widely recommended for the prevention of pre-
eclampsia in high-risk populations, and whilst there are
no specific data to support its use in KTRs, it seems rea-
sonable to follow this approach, adopted from other
guidelines [20, 143]. Outcomes of pregnancies fathered by
male KTRs are similar to the general population although
reporting bias is difficult to account for [51, 220].
There are very little data surrounding the use of female
contraception in KTRs and so it seems sensible to extrapo-
late from the general population with similar cautions and
contraindications [61]. A number of hypothetical risks asso-
ciated with specific forms of contraception have not been
confirmed in observational studies, though the data quality
is poor [8].
Whilst ESRD is a state of reduced fertility, the rates of fe-
male subfertility and infertility in KTRs are largely un-
known. There are a small number of case reports of
successful outcomes following in vitro fertilisation in KTRs,
albeit with similar complications as seen in KTRs with con-
ventional pregnancy [159]. Further research is needed in
this area. Sirolimus and presumably other m-TORi are as-
sociated with oligospermia, which appears to be reversible
on cessation of treatment [8, 151, 159].
Guideline 11.5 – KTR: sexual function
We suggest:
 Men should be counselled about the possible risks of
impotence following transplantation surgery that
involves the internal iliac artery (2D)
 Specific enquiry should be made regarding sexual
dysfunction, preferably at an annual review clinic (2D)
 Care pathways for dealing with sexual dysfunction
should be established (2D)
 Sildenafil is safe and effective in male KTRs not
taking nitrates (2D)
Audit Measures
 Prevalence of sexual dysfunction in the transplant
clinic
Rationale Sexual dysfunction is very common in both
men and women with advanced CKD and manifests with
decreased libido and erectile dysfunction. These prob-
lems are often improved after successful renal trans-
plantation but remain common [62, 131, 168]. Sildenafil
is safe and may be effective for erectile dysfunction in
KTRs [190].
Lay Summary
These guidelines cover the care of patients from the
period following kidney transplantation until the trans-
plant is no longer working or the patient dies. During the
early phase prevention of acute rejection and infection are
the priority. After around 3–6 months, the priorities
change to preservation of transplant function and avoiding
the long-term complications of immunosuppressive medi-
cation (the medication used to suppress the immune sys-
tem to prevent rejection). The topics discussed include
organization of outpatient follow up, immunosuppressive
medication, treatment of acute and chronic rejection, and
prevention of complications. The potential complications
discussed include heart disease, infection, cancer, bone
disease and blood disorders. There is also a section on
contraception and reproductive issues.
Immediately after the introduction there is a statement
of all the recommendations. These recommendations
are written in a language that we think should be under-
standable by many patients, relatives, carers and other
interested people. Consequently we have not reworded
or restated them in this lay summary. They are graded 1
or 2 depending on the strength of the recommendation
by the authors, and A-D depending on the quality of the
evidence that the recommendation is based on.
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